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ABSTRACT OF DISSERTATION

SUBSTRATE AND REGULATION OF MITOCHONDRIAL !-CALPAIN
!-Calpain is localized to the mitochondrial intermembrane space. Apoptosisinducing factor (AIF), which executes caspase-independent cell death, is also localized
to the mitochondrial intermembrane space. Following processing at the N-terminus, AIF
becomes truncated (tAIF) and is released from mitochondria. The protease responsible
for AIF processing has not been established. The same submitochondrial localization of
mitochondrial µ-calpain and AIF gives support to the hypothesis that mitochondrial µcalpain may be responsible for processing AIF. Atractyloside-induced tAIF release in rat
liver mitochondria was inhibited by cysteine protease inhibitor MDL28170, but not by
calpain inhibitors PD150606 or calpastatin. Moreover, µ-calpain immunoreactivity was
difficult to detect in rat liver mitochondria. In a mitochondrial fraction from SH-SY5Y cells,
incubation with 5 mM Ca2+ resulted in the activation of mitochondrial !-calpain but not in
AIF truncation. Finally, in hippocampal neurons calpain activation did not induce AIF
processing or nuclear translocation and AIF translocation to nucleus was calpain
independent. The localization of µ-calpain to the mitochondrial intermembrane space is
suggestive of its possible involvement in AIF processing, but direct experimental
evidence supporting such a role has been elusive.
We observed that mitochondrial !-calpain required high Ca2+ for activation. We
examined the hypothesis that the endogenous calpain inhibitor, calpastatin, may be
present in the neuronal mitochondria. Calpastatin was detected in the mitochondriaenriched fraction obtained from rat cerebral cortex and SH-SY5Y cells. The
mitochondrial calpastatin was resistant to proteinase K digestion, indicating localization
internal to the outer mitochondrial membrane. Submitochondrial fractionation revealed
that the calpastatin was localized to the mitochondrial intermembrane space and
mitoplasts (inner mitochondrial membrane and matrix) but not to the mitochondrial outer
membrane fraction. Mitochondrial calpastatin was not detected when mitoplasts were
incubated with proteinase K, suggesting that calpastatin is not present in the matrix. The
N-terminus of XL domain of calpastatin, when fused to GFP and transfected to SH-SY5Y
cells showed mitochondrial localization and thus confirmed the presence of a
mitochondrial targeting sequence in calpastatin. Together, these results demonstrate the
presence of calpastatin in the neuronal mitochondrial intermembrane space, the same
submitochondrial compartment as mitochondrial !-calpain. This finding explains the high
Ca2+ requirements for mitochondrial !-calpain activation.

KEYWORDS: Calpain, Mitochondria, Calpastatin, Apoptosis-inducing factor,
Caspase-independent cell death.
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Chapter one
Introduction
“A fact is a simple statement that everyone believes. It is innocent, unless found guilty. A
hypothesis is a novel suggestion that no one wants to believe. It is guilty, until found
effective.”- Edward Teller
A. Preface
“To be at the right place at the right time makes all the difference” - This adage
underscores the importance of place in terms of deciding one’s fate. This simple fact of
life can be extrapolated into biomedical sciences where location of a protein can
significantly affect its function. At one place it may be harmless but at another place it
may wreck havoc in cell. There are many examples for the above mentioned statement
such as Bax, a member of BCL-2 family of pro-apoptotic proteins, is harmless in the
cytosol but after appropriate trigger translocates from the cytosol to the mitochondria,
oligomerizes and induces cell death (Roucou and Martinou, 2001), NFkB, a transcription
factor that localizes to the cytosol in unstimulated cells, but the nuclear translocation of
the same induces expression of several genes (Lenardo and Baltimore, 1989), or
Cytochrome C (CytC) that is involved in cell survival in the mitochondrial intermembrane
space (IMS), but once in cytosol leads to apoptosis (Liu et al., 1996). Thus, the
subcellular localization of various proteins is indeed a very intelligent means of
regulating functional consequences inside the cellular milieu. Calpains, the family of nonlysosomal neutral cysteine proteases, were thought be exclusively cytosolic (Murakami
et al., 1981; Lane et al., 1992; Takeuchi et al., 1992; Molinari and Carafoli, 1997; GilParrado et al., 2003; Goll et al., 2003; Wang et al., 2005). Recently certain isoforms of
calpain have been reported to be present in the mitochondria (Garcia et al., 2005;
Arrington et al., 2006; Ozaki et al., 2007; Badugu et al., 2008). The functional
significance of calpain’s mitochondrial localization has not been fully addressed,
possibilities being modulation of electron transport chain components, mitochondrial
fusion and fission, mitochondrial enzymatic reactions or mitochondria mediated-cell
death. Regulation of mitochondrial calpains is another domain that requires substantial
investigation.
This dissertation is an effort to address the issue regarding the functional
significance of !-calpain’s mitochondrial localization and its regulation. We explored the
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relationship between mitochondrial µ-calpain and caspase-independent cell death
executioner protein, apoptosis-inducing factor (AIF). We also add to the knowledge of
regulation of mitochondrial calpains by demonstrating the presence of calpain inhibitor,
calpastatin, in the mitochondrial intermembrane space. We report, for the first time,
presence of a mitochondrial targeting sequence in the N-terminus of calpastatin’s XL
domain, which not only suggests the possible mechanism of calpastatin import into the
mitochondria but also provides a novel function to the yet uncharacterized XL domain of
calpastatin.

B. CNS Injury
Central nervous system (CNS) injuries resulted in death of about 5.8 million
people all over the world in 1998 (Kazanis, 2005). CNS injuries can be broadly classified
as acquired and non-acquired injuries. Acquired CNS injury is the damage to the CNS
postnatal. This includes traumatic CNS injuries such as traumatic spinal cord injury
(tSCI) and traumatic brain injury (TBI) and non-traumatic CNS injuries such as
substance abuse and infection. Non-acquired CNS injuries include neurodegenerative
disorders such as Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s
disease, multiple sclerosis, Parkinson’s disease. Traumatic CNS injuries (tSCI and TBI)
have been tagged as a hidden epidemic. The annual incidence of traumatic CNS injuries
in the United States alone is about 1.4 million (National center for injury prevention and
control) (CDC, 2006), which represents one injury every half minute. Majority of the
individuals afflicted are young healthy male adults - tSCI (males 1.5 times more than
females) from age 0 to 4 and 15 to 19 and TBI (males 4 times more than females) from
18 to 35 years of age. Approximately 50,000 individuals die and about 246,000 are
hospitalized (including 10,000 paralyses) due to traumatic CNS injuries (TBI and
tSCI)(CDC, 2006) in the United States. Traumatic CNS injuries compromise an
individual’s sensory, motor, cognitive, executive, and emotional functions. They may also
lead to chronic pain, spasticity, infertility, lack of independence and compromised life
expectancy. Types of disability and symptoms vary greatly depending on the severity
and location of injury. Traumatic CNS injuries are also associated with huge financial
burden - US $ 60 billion/year for direct and indirect cost of TBI (TBI, 2000) and $ 9.7
billion/year for tSCI (SCI, 1998). Therefore there is immense need to accrue great efforts
in this arena of biomedical sciences to uncover key players in the pathophysiology of
2

traumatic CNS injuries. This understanding will lead to the identification of novel targets
that can be exploited for therapeutics, to help people suffering with pain and save
economy from the burden of billions of dollars.
Efforts in basic sciences have delineated certain hallmark features in the
pathophysiology of traumatic CNS injuries, including the revelation that the majority of
traumatic CNS injuries are biphasic in nature (Weil et al., 2008). First is the primary
phase of mechanical damage, which occurs due to the impact and transfer of a large
amount of kinetic energy, leading to membrane disruption, hemorrhage, ischemia, and
acute energy failure (Pettus et al., 1994; Bramlett and Dietrich, 2004). It is possible to
prevent/reduce the primary mechanical damage by observing precautionary measures
such as wearing helmets but it is practically impossible to treat the primary damage
because it is instantaneous. The primary phase is followed by a secondary phase which
lasts for days to weeks and thus provides an interventionally feasible window of
opportunity for treatment (Kermer et al., 1999). Besides the long course, the secondary
phase manifests a relatively better orchestered cascade of pathophysiological events
such as mechanically-induced neuronal depolarization, opening of voltage gated ion
channels, increased neuronal excitation and subsequent excessive release of excitatory
amino acid neurotransmitter - glutamate (Fonnum, 1984; Liu et al., 1991; Farooque et
al., 1996; McAdoo et al., 1999). Excessive glutamate in the CNS further enhances
neuronal excitability and increases intracellular Ca2+concentration (Choi, 1988), leading
to excitotoxicity (Olney, 1969). Excitotoxicity manifests severe intracellular derogatory
changes including activation of phospholipases and protein kinases, disruption of
mitochondrial calcium homeostasis and membrane potential (!"), increased reactive
oxygen species (ROS) formation, calcium deregulation, and calpain activation (Lipton
and Rosenberg, 1994; Rego and Oliveira, 2003; Park et al., 2004; Weil et al., 2008). All
of these above mentioned events culminate in severe mitochondrial dysfunction, release
of IMS proteins into cytosol, and initiation of apoptotic and necrotic pathways, resulting in
massive tissue loss (Tator and Fehlings, 1991; Young, 1993).
Elevation of the intracellular calcium is one of the chief downstream events in
secondary neurodegeneration (Happel et al., 1981; Moriya et al., 1994; Saatman et al.,
1996b; Yamashima, 2000). One indispensible component of calcium deregulation is the
overactivation of calpains, which contribute significantly to the neuropathology following
traumatic CNS injury (Banik et al., 1997; Posmantur et al., 1997; Springer et al., 1997;
3

Zhao et al., 1998; Schumacher et al., 1999; Schumacher et al., 2000; Zhang et al.,
2000). Thus calpain seems to be a rational target for therapeutics (Zhang et al., 2003;
Yu and Geddes, 2007). Hence a better understanding of calpains, defining its substrates
and regulation, would help immensely in addressing not only the issue of secondary
neuronal damage following various CNS injuries like TBI, tSCI, ischemia, and stroke but
also other forms of calpainopathies.

C. Calpain
1. Calpain - Introduction
Calpains (EC 3.4.22.17 ; Calcium-dependent protease with papain-like activity)
were discovered by Guroff in 1964 (Guroff, 1964). Calpains are a family of well
conserved 16 non-lysosomal, intracellular, neutral cysteine proteases (Ono et al., 1999;
Huang and Wang, 2001) implicated in necrotic form of cell death in both C. elegans and
mammals (Syntichaki et al., 2002; Pang et al., 2003). Calpains are found in all
vertebrates and their homologues are found in invertebrates, plants and fungi (Czogalla
and Sikorski, 2005). Calpains are classified on the basis of tissue distribution, as
ubiquitous and tissue specific calpains, and on the basis of structure, as typical and
atypical calpains (Sorimachi et al., 1994; Suzuki et al., 1995; Sorimachi et al., 1997a).
Typical calpains are heterodimers consisting of a large catalytic subunit and a small
regulatory subunit (Sorimachi and Suzuki, 2001) (Fig 1.1). The large catalytic subunit is
an 80 kD peptide and has four domains (based on the resolved crystal structure of mcalpain) (Hosfield et al., 1999) (Fig 1.1). Domain I is a 18aa N-terminus that interacts
with domain VI and is important for the stability of the heterodimer, Domain II has the
catalytic triad of the enzyme and is divided into domain IIa containing the active site Cys
and IIb containing His and Asn, Domain III is likely to be important for phospholipid and
calcium binding (Bevers and Neumar, 2008) and also has a stretch of 17aa as a linker
domain, and Domain IV has five EF hands for binding to calcium (Goll et al., 2003) (Fig
1.1). The small regulatory subunit is 28 kD and has two domains, namely domain V
which is the N-terminal (Imajoh et al., 1986) glycine rich hydrophobic domain and
domain VI which has five EF hands for binding to calcium (Ohno et al., 1986; Maki et al.,
1997) (Fig 1.1).
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2. Calpain - Functions
Calpains are involved in various physiological functions such as cell cycle
progression (Zhang et al., 1997), proliferation (Zhang et al., 1996), differentiation
(Grynspan et al., 1997a; Patel and Lane, 2000), migration (Franco et al., 2004; Satish et
al., 2005; Wu et al., 2006), synaptic remodeling and long term potentiation (Tomimatsu
et al., 2002), embryonic development (Arthur et al., 2000), meiosis and mitosis
(Schollmeyer, 1988; Santella et al., 2000) as well as in pathological states including
muscular dystrophy (Richard et al., 1995), diabetes (Horikawa et al., 2000), Alzheimer’s
disease (Saito et al., 1993; Grynspan et al., 1997b; Mark et al., 1997; Tsuji et al., 1998),
Huntington’s disease (Gafni and Ellerby, 2002; Lee et al., 2006), Parkinson’s disease
(Crocker et al., 2003), cataract (Nakamura et al., 2000), multiple sclerosis (Shields et al.,
1999), neuronal ischemia (Saido et al., 1993b; Roberts-Lewis et al., 1994), and
obsessive compulsive disorder (Mundo et al., 1997).
Calpains are also involved in the traumatic brain and spinal cord injuries (Kampfl
et al., 1996; Springer et al., 1997; Ray et al., 1999; Pike et al., 2001; Goll et al., 2003; Liu
et al., 2004). Calpain activation peaks within 1-4 h post traumatic injury and leads to
damage in grey matter neurons, white matter axons, oligodendrocytes, myelin, and
induces inflammatory response (Wang and Yuen, 1994; Springer et al., 1997; Zhang et
al., 2000; Zhang et al., 2003). Calpain-mediated proteolysis occurs for 24 h in grey
matter (Ray et al., 1999) and up to two weeks in white matter (Zhang et al., 2000).
Calpain inhibition is neuroprotective following tSCI (Iwasaki et al., 1985; Iwasaki, 1987;
Banik et al., 1998; Ray et al., 2000; Ray et al., 2001b, a; Ray et al., 2003; Wingrave et
al., 2003; Zhang et al., 2003; Yu and Geddes, 2007), TBI (Saatman et al., 1996b;
Posmantur et al., 1997), and NMDA mediated excitotoxicity in primary neurons (Brorson
et al., 1995).

3. Calpain - Activation
Calpain activation occurs due to the calcium induced conformational change that
reduces the distance between Cys-105 and His-262, Asn-286, so as to form the catalytic
triad (Hosfield et al., 1999). The Cys acts as a nucleophile and attacks on the peptidyl
carbonyl, forming a tetrahedral intermediate that releases amine product and acylenzyme complex. The acyl-enzyme complex subsequently releases carboxyl product
and the intact enzyme (Storer and Menard, 1994). Calpain activation leads to the
5

disassociation of the heterodimer (Yoshizawa et al., 1995; Suzuki et al., 2004) as well
induces its autoproteolysis (Dayton, 1982; Cong et al., 1989; Edmunds et al., 1991;
Michetti et al., 1997). Autoproteolysis makes disassociation irreversible and also
decreases the amount of calcium required for activation by both m and !-calpain by
1/10th (Edmunds et al., 1991; Goll et al., 2003). Autoproteolysis occurs at the N-terminus
and removes 27aa from the 80 kD !-calpain large catalytic subunit to make it 76 kD,
removes 18aa from 80 kD m-calpain large catalytic subunit to make it 78 kD and
removes 91aa from the 28 kD small regulatory subunit to make it 18 kD (Suzuki, 1990;
Graham-Siegenthaler et al., 1994). There are two ways to identify intracellular calpain
activation. One is by looking for signature proteolysis of a known calpain substrate,
commonly used marker is 150 kD and 145 kD bands of alpha II-spectrin (Pike et al.,
1998; Wang, 2000). A second method is by examining autoproteolysis of calpain large
catalytic subunits, though the lack of autolysis does not mean calpain is not active
(Molinari et al., 1994; Yoshizawa et al., 1995; Elce et al., 1997; Goll et al., 2003). Being a
cysteine protease calpain is highly susceptible to oxidation. Oxidation of calpains does
not affect its autoproteolysis capability but inhibits its activity completely (Guttmann et al.,
1997).

4. Calpain – Inhibitors
The majority of calpain inhibitors are peptide analogues (Wang, 1990; Wang and
Yuen, 1997) and recent ones are non-peptide calpain inhibitors (Wang et al., 1996;
Donkor, 2000). Calpain inhibitors can be classified broadly as – peptidyl epoxides,
peptidyl aldehydes, peptidyl alpha ketoamids, or non-peptide inhibitors (Carragher,
2006). MDL28170 used in our studies is a peptidyl aldehyde inhibitor, which are the
largest group of calpain inhibitors. These are reversible inhibitors that react with the
active site thiol of the calpains (Carragher, 2006). First peptidyl aldehydes were isolated
from streptomyces (Saito et al., 1972) and later generation inhibitors were made by
substituting the N-terminal lipophilic group and hence termed as N-protected dipeptidyl
aldehydes (Yano et al., 1993) e.g. MDL28170 (Mehdi et al., 1988). MDL28170 has
shown promising results in in vivo models of spinal cord injury, diffuse brain injury,
axonal damage, cerebral ischemia and Parkinson’s disease (Iwasaki et al., 1985;
Iwasaki et al., 1987; Hong et al., 1994; Banik et al., 1998; Buki et al., 2003; Crocker et
al., 2003; Zhang et al., 2003; Yu and Geddes, 2007; Yu et al., 2008). PD150606 used in
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our studies is a non-peptide, reversible, non-competitive calpain inhibitor that binds to
allosteric site of calpain and demonstrates better pharmacokinetics (Wang et al., 1996;
Carragher, 2006). PD150606 is alpha mercaptoacrylic acid (Wang et al., 1996), cell
permeable and extremely selective for calpains. It binds to domain VI of calpains in the
same region as the subdomain C of calpastatin (Lin et al., 1997; Todd et al., 2003).
PD150606 has been shown to be effective in models of cataract, cerebellar slices
suffering from excitotoxicity, and hypoxic injury in renal proximal tubes (Mathur et al.,
2000; Liu et al., 2001; Xu et al., 2003). Though significant progress has been made in
improvising calpain inhibitors it has to be realized that calpain inhibitors have certain
lacunae such as they are non-specific (Banik et al., 1997; Crocker et al., 2003), have low
potency, poor aqueous solubility, short plasma half-life, and poor BBB crossing ability
(Figueiredo-Pereira et al., 1994; Wang and Yuen, 1994; Chatterjee et al., 1998). Hence
novel approaches are required for calpain inhibition strategies to work in the CNS injury
paradigms.

5. Calpain isoforms - !-calpain the pathologic isoform
Calpain 1,2,3,5,10 and two small regulatory subunit isoforms are reported in the
brain (Ma et al., 2001; Goll et al., 2003; Konig et al., 2003; Waghray et al., 2004).
Predominant typical ubiquitous isoforms present in the central nervous system are micro
(µ) and milli (m) calpains (Croall and DeMartino, 1991). They have a similar small
regulatory 28 kD subunit (calpain 4), similar if not identical substrate specifities in vitro,
and are sensitive to the same synthetic calpain inhibitors (Bevers and Neumar, 2008).
But they have different large catalytic subunits (50% sequence homology) and require
different amounts of calcium for activation in vitro - micromolar concentration of calcium
(2 µM to 80 µM) for half maximal activity for !-calpain and millimolar concentration of
calcium (0.2 mM to 0.8 mM) for half maximal activity for m-calpain (Suzuki, 1991; Saido
et al., 1993a; Saido et al., 1994; Sorimachi et al., 1997a).
A convincing reason for the redundancy of similar calpains in the biological
system is not evident although there are some speculations in this regard. Because of
the low calcium requirement for activation, µ-calpain was assumed to be the
physiological isoform of calpain but based on its distribution and cleaved substrate
spectrin (Siman et al., 1985; Roberts-Lewis et al., 1994) µ-calpain may be a pathological
isoform. This thought is further supported by the fact that µ-calpain knockouts are viable
7

and show no major phenotypic changes except platelet dysfunction (Azam et al., 2001)
whereas the m-calpain knockouts die at pre-embryonic stage due to failure of blastocyst
to implant (Dutt et al., 2006). Moreover, µ-calpain knockout does not alter the proteolysis
of majority of cytoskeleton substrates of calpain (Franco et al., 2004) and µ-calpain
knockdown is protective in NMDA excitotoxicity in hippocampal slice cultures (Bednarski
et al., 1995) and disassociated neuronal cultures (Cao et al., 2007). It has also been
found that m-calpain is more abundant in the CNS but it is µ-calpain that is responsible
for the damage after ischemia and hence responsible for neurodegeneration (Saido et
al., 1993b; Roberts-Lewis et al., 1994; Bevers and Neumar, 2008). Further it is shown
that !-calpain mediates oxidant-induced hepatocyte cell death (Miyoshi et al., 1996) and
ischemic hippocampal neuronal cell death (Rami et al., 2000). These set of evidence
bolsters the thought that µ-calpain is a pathologic isoform.
One paradox in the field of calpains has been that in vivo calcium concentration
never reaches up to micro or millimolar concentration, suggesting that calpain activation
must have additional components which would make its activation easier (Croall and
DeMartino, 1991; Goll et al., 2003; Hood et al., 2003), such as preferred subcellular
localization in the proximity of calcium stores. !-Calpain, which has evidence of being a
pathologic calpain isoform, has been reported to be present in the mitochondrial
intermembrane space (Beer et al., 1982; Tavares and Duque-Magalhaes, 1991; Garcia
et al., 2005; Cao et al., 2007; Badugu et al., 2008). This localization of !-calpain would
make its activation faster, easier, and reliable. This location also suggests a putative role
of !-calpain in mitochondria based pathological scenarios. Hence, there is a
convincing rationale to explore both the substrates and regulation of the
mitochondrial !-calpain, which would add immensely to the knowledge of
calpain’s role in various diseases particularly of the mitochondrial origin.

6. Calpain - Substrates
Calpains process their substrates at the interdomain boundaries such that it not
only modulates their activity and function (Croall and DeMartino, 1991; Friedrich and
Bozoky, 2005) but also acts as a cell signaling mechanism. Calpain substrates include
various classes of proteins such as cell signaling molecules, membrane proteins,
intracellular enzymes, and structural proteins (Lynch and Baudry, 1987; Bi et al., 1998;
Potter et al., 1998; Blomgren et al., 1999; Hasselgren, 1999; Wang, 2000; Vinade et al.,
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2001; Huang et al., 2004; Liu et al., 2004; Kuchay et al., 2007). Most of the calpain
substrates have been identified using in vitro calpain cleavage assays and thus do not
necessarily reflect calpain target proteins in the cell (Liu et al., 2004). Sequence analysis
of various calpain substrates has not yielded a consensus sequence or a definitive
cleavage site (Cuerrier et al., 2005) and it is believed that calpain recognizes the global
structural elements in the intact protein (Tompa et al., 2004). Thus all of the calpain
substrates are yet not fully characterized. Calpain mediated cytoskeletal damage in the
CNS injury may be the prime reason for cells to die (Saatman et al., 1996a; Saatman et
al., 1998; Buki et al., 1999; Hall et al., 2005) but calpain inhibition mediated
neuroprotection was not in harmony with decreased cytoskeletal damage (Saatman et
al., 2000; Kupina et al., 2001). This finding supports a possibility of other calpain
substrate/s being mediators of cell death. Thus, the trauma-induced and calpainmediated mechanism that contributes to the neurodegeneration is still not known. Novel
calpain substrates have been identified recently such as CRMP-3 (Hou et al., 2006),
Na+-Ca2+ exchanger (NCX) (Bano et al., 2005), and mitochondrial protein apoptosisinducing factor (AIF)(Gao and Dou, 2000; Polster et al., 2005). The unknown calpain
substrate that mediates the CNS injury pathology, the evidence that !–calpain is
the pathologic isoform and is located in the mitochondrial intermembrane space,
and studies demonstrating that AIF, a mitochondrial intermembrane space
protein, is a !-calpain substrate gave enough rationale to test the hypothesis that
mitochondrial !-calpain mediated AIF processing and release.

7. Mitochondria and apoptosis-inducing factor (AIF)-Old dog new tricks
(i) Mitochondria
Mitochondria are a good example of successful symbiotic relationship between
an anaerobic eukaryotic cell and an aerobic bacterium for over 800 million years (Martin
and Koonin, 2006). Mitochondria are primarily involved in energy production via citric
acid cycle, electron transport chain and oxidative phosphorylation and are also
extensively involved in calcium homeostasis, cell death, beta-oxidation of fatty acids,
urea cycle, heme synthesis, ROS production, lipid metabolism, Xenobiotic metabolism,
glucose sensing/insulin regulation, interconversion of amino acids and hormone
metabolism (Reichert and Neupert, 2002; Brookes et al., 2004; Hajnoczky et al., 2006).
Mitochondria are tubular, branched, and highly dynamic double membranous organelles.
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apoptosis proteins following release from IMS (Du et al., 2000; Verhagen et al., 2000).
Omi/HtrA2 is a mitochondrial serine protease (Li et al., 2002), upon release from
mitochondria promotes cell death by binding with inhibitor of apoptosis proteins (IAP)
(Hegde et al., 2002; Verhagen et al., 2002). Apoptosis-inducing factor, an
oxidoreductase, projects from inner mitochondrial membrane attachment into the IMS
and the protease mitochondrial !-calpain, whose function is yet unknown, is also present
in the IMS. The IMS is further divided into the external IMS - between outer and inner
mitochondrial membrane and internal IMS - between the cristae membrane separated by
the cristael junctions (Frey and Mannella, 2000; Frey et al., 2002; Herrmann and Hell,
2005). Modulation of cristael junction for letting proteins flow from internal IMS to
external IMS and vice versa is essential for cell death (Scorrano et al., 2002).
Mitochondria are the key regulators of cell death (Smith et al., 2008). On the
basis of morphology cell death was broadly classified as – apoptosis, mediated by
mitochondrial protein CytC via caspases and necrosis, mediated by mitochondrial
permeability transition pore formation (Kroemer and Reed, 2000). Recent classification
of cell death takes into account not only the morphology but also the underlying
biochemical mechanism and thus other atypical modalities of cell death namely
autophagy, cornification, mitotic catastrophe, anoikis, paraptosis, pyroptosis,
pyronecrosis, necroapoptosis and entosis have come into picture (Kroemer et al., 2009).
Caspase-independent cell death (CICD) has recently been recognized as a programmed
cell death pathway presenting apoptotic morphology but without the activation of
caspases and phosphatidylserine externalization, relatively slower kinetics and
demonstrating only peripheral nuclear condensation (Penninger and Kroemer, 2003;
Ekert et al., 2004). Caspase-independent cell death is important in both physiological
and pathological situations, particularly in adult neurodegeneration (Stoka et al., 2006),
displays wide variety of features depending on cell type and cell death stimuli, and
essentially manifest mitochondrial outer membrane permeabilization (Tait and Green,
2008). Apoptosis-inducing factor, an IMS protein, is the key protein that actively
contributes to CICD. Caspase-independent cell death pathway thus originates at
mitochondria and involves AIF.
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(ii) Apoptosis-inducing factor
Apoptosis-inducing factor (AIF) is a 62 kD mitochondrial flavoprotein homologous
to the bacterial NADH oxidoreductase (Susin et al., 1999). It is phylogenetically
conserved, encoded by a gene of 16 exons located in Xq 25-26 and A6 of chromosome
X in humans and mice (Susin et al., 1999). There are four additional isoforms of AIF
(Fig1.2). Apoptosis-inducing factor-exB (AIF-eXB), results from alternative usage of exon
2b (Loeffler et al., 2001). Apoptosis-inducing factor-short (AIF-sh) results from an
alternate transcriptional start site at intron 9 and is a cytosolic protein corresponding to
the C-terminal domain of AIF (353-613 amino acids) that retains cell death inducing
properties (Delettre et al., 2006b). Apoptosis-inducing factor-short 2 (AIF-sh2) contains a
previously unknown exon between exons 9 and 10 of AIF. It localizes to the
mitochondria, has oxidoreductase properties, but does not show nuclear translocation
and DNA damage and it is absent from normal brain tissue (Delettre et al., 2006a).
Apoptosis-inducing factor-short3 (AIF-sh3) is encoded by exon 1-9b with alternative
splicing of exon 2 and 9. Apoptosis-inducing factor (AIF) is required for embryonic
development (Joza et al., 2001) and loss of AIF causes abnormal cell death in embryos
at later stage (post E9) but earlier growth is normal (Brown et al., 2006a). Harlequin mice
are AIF hypomorphs, showing 80% decline in AIF protein (Klein et al., 2002).
Apoptosis-inducing factor (AIF) is synthesized as a 67 kD precursor protein in the
cytosol having a dual mitochondrial localization signal (MLS) (Fig 1.3) (Susin et al.,
1999; Otera et al., 2005). Following mitochondrial import its MLS is removed at aa
position 53/54 and it is anchored in the mitochondrial inner membrane as a 62 kD Type I
protein (mature AIF) with its N-terminus in the matrix and C-terminus in the mitochondrial
IMS (Otera et al., 2005) (Fig1.3). In normal conditions mature AIF acts as an
oxidoreductase protein and free radical scavenger (Klein et al., 2002; Lipton and BossyWetzel, 2002), plays role in electron transport chain (ETC) (Vahsen et al., 2004; Joza et
al., 2005), and maintains mitochondrial structure (Cheung et al., 2006), whereas in
pathological states it gets cleaved from the inner membrane attachment by an unknown
protease (Otera et al., 2005), becomes truncated AIF (tAIF-57 kD), and translocates
from the mitochondria to the nucleus via an internal C-terminal NLS and leads to
extensive large scale DNA fragmentation (50 kB), chromatin condensation, and CICD
(Susin et al., 1999; Daugas et al., 2000a; Joza et al., 2001; Penninger and Kroemer,
2003; Cande et al., 2004; Plesnila et al., 2004) (Fig 1.3).
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Apoptosis-inducing factor (AIF) mediated CICD is reported in various
neurodegeneration models. Nuclear translocation of AIF is observed in the focal cerebral
ischemia (Plesnila et al., 2004), in vulnerable neurons after transient cerebral ischemia,
in neuronal cultures exposed to oxygen glucose deprivation (Cao et al., 2003), in the rat
model of TBI, in the neuronal cultures exposed to peroxynitrite (Zhang et al., 2002), in
tSCI (Yu et al., 2006a) and in a DNA damage model (Susin et al., 1999). Apoptosisinducing factor (AIF) release from the mitochondria and its translocation to the nucleus is
documented in the MPP+ model of Parkinson’s disease (Liou et al., 2005; Wales et al.,
2008) and it is a prominent pathway of cell death following NMDA exposure in primary
mouse cortical neurons, occurring even before the release of Cytochrome C (Wang et
al., 2004). Apoptosis-inducing factor (AIF) is the central player in mediating PARP-1
dependent cell death (Yu et al., 2002), also called Parthanatos (Harraz et al., 2008).
TNF-alpha induced cell death of oligodendrocytes is also mediated by AIF translocation
(Jurewicz et al., 2005). AIF is released into the cytosolic fractions in Fas-mediated
oligodendrocyte death (Austin and Fehlings, 2008).
Inhibition of AIF translocation is a proposed mechanism for protective effects of
hepatocyte growth factor (HGF) treatment against the excitotoxic cell death of
hippocampal neurons (Ishihara et al., 2005). Apoptosis-inducing factor (AIF) neutralizing
antibody confers protection in p53 induced neuronal death (Cregan et al., 2004). Heat
shock protein-70 (HSP70) overexpression sequesters AIF and prevents neonatal
hypoxic/ischemic brain damage (Matsumori et al., 2005). Apoptosis-inducing factor (AIF)
hypomorphs (Hq mice) are resistant to both PAR and NMDA toxicity and neutralizing
antibodies of PAR or PARG overexpression prevented the AIF translocation to nucleus
and cell death (Andrabi et al., 2006; Yu et al., 2006b). Harlequin (Hq) mice are protective
in both BAX-dependent and BAX-independent neuronal injuries (Cheung et al., 2005)
and show neuroprotection compared to littermate wild type mice in neonatal cerebral
hypoxia-ischemia (Zhu et al., 2007). All these evidence highlight the importance of AIFmediated CICD and possible positive implication of inhibiting AIF translocation to the
nucleus in neurodegeneration. Caspase-independent cell death (CICD) being mediated
by AIF release and translocation makes it imperative to understand the mechanism of
AIF release from the mitochondria. The localization of µ-calpain to the mitochondrial
intermembrane space (Cao et al., 2007; Badugu et al., 2008), the same
submitochondrial compartment as AIF, and evidence for involvement of a unknown
cysteine protease in AIF processing and release (Otera et al., 2005; Yuste et al., 2005),
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places great credence to the possibility of mitochondrial !-calpain being the protease
which processes AIF.

(iii) Mitochondrial permeability transition pore
Mitochondrial permeability transition (mPT) is a sudden increase in the inner
mitochondrial membrane permeability resulting from opening of a non-specific channel
permeable to molecules of up to 1500 Da (Haworth and Hunter, 1979; Szabo and
Zoratti, 1992). mPTP causes dissipation of mitochondrial membrane potential, loss of
mitochondrial ion homeostasis, impairment of ATP synthesis, diffusion of solutes down
their concentration gradient to cytosol, massive influx of water, IMM unfolding, passive
mitochondrial swelling that can be measured as decrease in light scattering in
suspended mitochondria (Halestrap, 1999), calcium efflux to cytosol, OMM rupture and
release of various death-effecter mitochondrial proteins like Cytochrome C to the cytosol
(Kim et al., 2003; Sullivan et al., 2005). mPTP can be induced by multitude of factors
such as Ca2+, Zn2+, mitochondrial toxins, NO, peroxynitrite, 4-hydroxynonenal (Bernardi,
1996), increase in the matrix calcium concentration, "# (Bernardi, 1992), reactive
oxygen species, inorganic phosphates (Bernardi et al., 1998) matrix pH (Nicolli et al.,
1993), lack of adenine nucleotides (Haworth and Hunter, 1979) or use of compounds like
atractyloside (Atr) that locks adenine nucleotide translocase (ANT) in the cytoplasmic
face (Petronilli et al., 1994). Inhibitors of mPTP include CsA, Mg+2, ADP, and
Bongkerakic acid (Bernardi, 1996). The components of mPTP are under investigation,
but a general consensus is that it is composed of the outer mitochondrial membrane
protein VDAC, matrix protein Cyclophilin D (CypD - a peptidyl-prolyl isomerase) and IMM
protein ANT (Crompton et al., 1998; Woodfield et al., 1998; Kokoszka et al., 2004;
Baines et al., 2007) with a possibility of involvement of other proteins such as peripheral
benzodiazepine receptor (PBR), hexokinases and creatine kinase (Kim et al., 2003).
Mitochondria buffer the increased cytosolic calcium during excitotoxicity. Mitochondrial
accumulation of calcium beyond the threshold results in the migration of CypD from
matrix to bind to ANT and induces a conformational change in ANT to facilitate the
mPTP formation. mPTP is also known to act in a low conductance mode that provides
transitory openings and allows solutes of less than 343 Da to leak out and thus helps in
signal transduction (Ichas and Mazat, 1998). This is the phenomenon of flickering,
causing transient depolarization and calcium loss followed by restoration of "# and
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internal calcium (Ichas et al., 1997; Kerr et al., 1999; De Giorgi et al., 2000; Kindler et al.,
2003; Gerencser and Adam-Vizi, 2005).
Cyclophilin-D (CypD) knockout mice show neuroprotection against CICD but not
against apoptosis (Baines et al., 2005; Basso et al., 2005; Nakagawa et al., 2005).
Cyclosporine A (CsA), an mPTP inhibitor (Fournier et al., 1987; Crompton et al., 1988;
Broekemeier et al., 1989) which targets CypD, inhibits AIF translocation to the nucleus in
transient hypoglycemic neurons (Ferrand-Drake et al., 2003) and release of tAIF (Petit et
al., 1998) in the rat liver isolated mitochondria (Polster et al., 2005). These observations
demonstrate the dependence of CICD i.e. AIF processing and release on mPTP.
Mitochondrial permeability transition pore (mPTP) leads to huge calcium efflux and high
calcium concentration in the IMS, where mitochondrial !-calpain resides. Cyclosporine-A
(CsA) also prevented calpain activation in hypoglycemic neurons (Ferrand-Drake et al.,
2003), suggesting calpain activation to be downstream of mPTP. Thus it is highly likely
that mitochondrial !-calpain could be the protease that plays a central role in CICD by
processing AIF following mPTP formation. The central hypothesis tested in the
chapter 3 of the dissertation is that following mitochondrial permeability transition
pore formation (mPTP), mitochondrial µ-calpain is involved in the AIF processing
and release. Our results demonstrated that mitochondrial !-calpain is not involved in the
processing and release of AIF.
Studies performed in the isolated mitochondria in chapter 3 provided valuable
information about the mitochondrial !-calpain and AIF relationship in in vitro model. But
in a cell culture model additional factors may modulate the type of relationship which
exists between AIF and mitochondrial !-calpain. Various studies performed in cell
culture models have attributed different proteases in AIF processing and release,
including calpain (Takano et al., 2005; Artus et al., 2006; Wales et al., 2008; Mader et
al., 2009), mitochondrial calpain (Norberg et al., 2008) and !-calpain (Cao et al., 2007;
Ozaki et al., 2008). There are number of studies which suggest that outer mitochondrial
membrane permeabilization is an upstream event for AIF processing and release (Tait
and Green, 2008). AIF translocates to the nucleus on induction of apoptosis and
necrosis and this can be prevented by BCL-2 overexpression or BAX knockouts
(Daugas et al., 2000b; Cregan et al., 2002). Following glutamate stimulation of HT-22
neurons tBid translocates to the mitochondria, there is perinuclear mitochondrial
accumulation, loss of mitochondrial membrane potential and Bid inhibitor and Bid siRNA
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prevented the AIF release and translocation (Landshamer et al., 2008). All these are
indicative of absolute necessity for outer mitochondrial membrane permeabilization for
AIF proteolytic processing and mitochondrial release leading to subsequent AIF nuclear
translocation. It also suggests that either translocation of a protease, probably calpain or
cytosolic !-calpain or some other factor to the mitochondrial intermembrane space from
cytosol is required for AIF proteolytic processing and release. It is also possible that
some inhibitory component of calpain from mitochondrial intermembrane space is
released from mitochondria to the cytosol following OMM permeabilization and then AIF
processing, release and translocation can occur (Modjtahedi et al., 2006). Thus in
chapter 4 of the dissertation we studied the effect of calpain activation on AIF
processing and subcellular distribution in cell culture model following various
cellular stressors. These studies demonstrated that calpain activation does not
necessarily induce AIF processing, AIF nuclear translocation can occur independent of
calpain activity and AIF can translocate to the nucleus in full length mature 62 kD form
without any processing.

8. Calpain – Regulation
Regulation of activity is essential for proper function. Calpain activity is also finely
regulated by various mechanisms in the biological system, primary means of regulation
are modulating calcium concentration and interaction with its specific endogenous
inhibitors. Endogenous proteins such as alpha macroglobulin, L and H kininogens can
inhibit calpains, but calpastatin is the only specific endogenous inhibitor exclusively for
calpains with no other known function (Dayton et al., 1976; Croall and DeMartino, 1991;
Mellgren, 1991; Brustis et al., 1994; De Jongh et al., 1994; Shea et al., 1995).
Calpastatin is trypsin labile, heat resistant, and cannot cross the BBB and cell
membranes (Okitani, 1976; Goll et al., 2003). Calpastatin inhibits both the activation and
the catalytic activity of calpains (Cottin et al., 1981; Goll et al., 2003) in a reversible
calcium dependent manner (Cottin et al., 1981; Imajoh and Suzuki, 1985; Otsuka and
Goll, 1987).
Calpastatin does not bind to calcium itself but binds to calpain only in the
presence of calcium (Wendt et al., 2004; Hanna et al., 2007). Calpastatin exists in a coil
conformation in solution (Uemori et al., 1990; Konno et al., 1997) and has a migration
pattern that is 40-50% slower than its true molecular weight on SDS-PAGE (Takano and
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Murachi, 1982a; Maki et al., 1991). It is found only in vertebrate tissues, lower organisms
such as Drosophila, Caenorhabditis elegans and Saccharomyces cerevisiae do not
contain a calpastatin sequence (Goll et al., 2003). Calpastatin’s molecular mass ranges
from 17.5 kD to 84 kD and it has six domains (Goll et al., 2003). An amino terminal L
domain that lacks the inhibitory activity (Maki et al., 1987; Averna et al., 2001) followed
by four repetitive inhibitory domains of 140 aa each (Emori et al., 1987; Suzuki et al.,
1987; Goll et al., 2003). Each domain has three subdomains named as A, B and C
(Murachi et al., 1989) and each domain inhibits one calpain molecule (Maki et al., 1987).
Subdomain B binds near the catalytic center and inhibits the protease activity of calpain
whereas the subdomain A and C potentiate inhibition by subdomain B. An additional Nterminal XL domain has been identified in bovines (Cong et al., 1998). Calpastatin can
be cleaved by calpains due to an increase in the ratio of active calpain to calpastatin
(Sorimachi et al., 1997b) and this happens in tSCI (Ray et al., 2000).
The single gene on chromosome 5 encodes calpastatin in birds and mammals
(Inazawa et al., 1990; Cong et al., 1998) but there are various isoforms of calpastatin
due to alternative splicing (Lee et al., 1992a; Lee et al., 1992b; Takano et al., 1999),
exon skipping (De Tullio et al., 2007) and usage of different promoters (Imajoh et al.,
1987; Cong et al., 1998) (Fig1.4). One alternative isoform of calpastatin in the red blood
cells lacks L domain and first inhibitory domain (Takano and Murachi, 1982b). Rat brain
also contains multiple mRNAs for calpastatin (De Tullio et al., 1998) and multiple
isoforms in rat brain calpastatin are produced by distinct starting points and alternative
splicing of the N-terminal axons (De Tullio et al., 2007). The reason for presence of so
many isoforms of calpastatin is not known.
Other ways to regulate calpain activity is by translocation to the membranes,
autoproteolysis, disassociation of subunits, interaction with calpain activating proteins
(CAP) and phosphorylation (Croall and DeMartino, 1991; Melloni et al., 1996; Melloni et
al., 1998a; Suzuki and Sorimachi, 1998; Melloni et al., 2000; Liu et al., 2004). Subcellular
localization of a protein is also one of the chief mechanisms of regulating the activity by
“proximity to substrates and/or activators effect”. Thus for calpains, differential
subcellular localization of m and !-calpain is not only a mechanism to differentiate the
function of two isoforms by limiting their substrate accessibility but also a mechanism to
regulate activity by proximity to calcium store. Regulation of calpain activity can also be
achieved by modulating calpastatin levels, calpastatin phosphorylation and calpastatin’s
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subcellular localization (Pontremoli et al., 1988; Niapour et al., 2008). XL domain has
three phosphorylation sites by protein kinase A (PKA) (Murachi et al., 1989) that reduces
the activity of calpastatin to inhibit calpain (Crawford et al., 1993; Melloni et al., 1996).
Both protein kinase C (PKC) and PKA-mediated phosphorylation of calpastatin increases
its membrane association (Adachi et al., 1991) and PKA-mediated phosphorylation helps
to aggregate the molecule near the nucleus (Gil-Parrado et al., 2003) thereby
differentially compartmentalizing calpastatin and calpain in the cell. Calpastatin has an
amino terminal L domain having positive charged amino acids which plays a role in
subcellular localization of the molecule and its regulation (Mellgren et al., 1987; Mellgren,
1988; Mellgren et al., 1989). Elevated cytosolic calcium causes dephosphorylation of
calpastatin by phosphatases and promote cytosolic diffusion. Thus aggregation and
subcellular distribution of calpastatin are the mechanisms of regulating calpain activity
(Tullio et al., 1999).
Relatively little is known about the regulation of mitochondrial !-calpain. AcylCoenzyme A Binding Protein (ACBP) has been identified as a calpain activator (Melloni
et al., 2000) and has been found in the mitochondrial intermembrane space (Van Loo et
al., 2002b). It has been shown further that ACBP is a necessary factor for activation of
mitochondrial !-calpain following tBid or Bid incubation (Shulga and Pastorino, 2006). In
our studies we found that mitochondrial !-calpain is hard to activate and has very high
calcium requirement, one possibility could be the presence of calpastatin as a negative
regulator of mitochondrial !-calpain in the mitochondria. Thus chapter 5 of the
dissertation ventures into understanding the regulation of mitochondrial !-calpain
by probing for the presence of calpastatin in the mitochondria. We localize
calpastatin in the mitochondrial intermembrane space.
Human mitochondrial DNA is 16.6 kB circular DNA (Anderson et al., 1981). It has
37 genes and only 13 of those encode for proteins and all of them are components of
electron transport chain (ETC) (Schon, 2000; Garesse and Vallejo, 2001). Majority of the
mitochondrial proteins have to be synthesized in the cytosol and then imported into the
mitochondria (Poyton and McEwen, 1996; Scarpulla, 2002). Matrix proteins typically
have an N-terminal mitochondrial targeting sequence which forms amphipathic helix with
a hydrophobic and a positively charged side (von Heijne, 1986). These are imported via
interaction with translocase of outer membrane (TOM), translocase of inner membrane
23 (TIM23) and its motor in a ATP and membrane potential dependent manner
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(Herrmann and Hell, 2005). Topogenesis of mitochondrial outer-membrane !-barrel
proteins (TOB) complex along with TOM complex is used to integrate beta barrel
proteins in the OMM. TIM 22 complexes assists in insertion of proteins in IMM, which in
most cases are imported into the matrix first and then inserted into the inner
mitochondrial membrane (Neupert and Herrmann, 2007). The IMS proteins can be
imported by three mechanisms. Class I IMS proteins have a bipartite sequences, a
mitochondrial presignal and then a hydrophobic domain. These proteins interact with
TOM complex, then are pulled inside the mitochondria by TIM 23, undergo translocation
arrest and finally are inserted into the IMM by lateral insertion. Presequences or the
inner membrane anchors can be processed by proteases. Large proteins of IMS are
usually imported by this mechanism (Herrmann and Hell, 2005). Class II IMS proteins
are small in size (7-15 kD), lack N-terminal sequences and have cysteine residues that
can bind to cofactors or form disulfide bridges. Unfolded proteins pass through the TOM
complex and then folding traps these proteins in the IMS (Herrmann and Hell, 2005).
Class III IMS proteins bind to the membrane proteins in the outer or inner mitochondrial
membrane in the IMS (Herrmann and Hell, 2005). Calpastatin is nuclear encoded and
has to be imported into the mitochondrial IMS. Chapter 5 also addresses the issue
regarding the mechanism of calpastatin import into the mitochondria. Since
calpastatin is a large protein localized to the mitochondrial IMS, most likely means of its
import to mitochondria could be the N-terminus targeting sequence. This was confirmed
by sequence analysis and further experimentation demonstrating that first 30 aa at the
N-terminus of calpastatin are a mitochondrial targeting sequence.
The main goal of this dissertation was to test the possibility of AIF being a
mitochondrial "-calpain substrate and understand the regulation of mitochondrial "calpain. Localization of "-calpain to the mitochondrial IMS posed a subsequent logical
question regarding its function. The evidence in favor of "-calpain’s pathological role, its
mitochondrial IMS localization and presence of AIF in the IMS, made AIF the most
logical target of mitochondrial "-calpain. The hypothesis tested in chapter 3 was that
following mPTP formation mitochondrial µ-calpain processes and releases apoptosisinducing factor (AIF) from mitochondrial inner membrane attachment. We report that
mitochondrial "-calpain is not involved in the processing of apoptosis-inducing factor.
Chapter 4 further explored the role of calpains in AIF processing and subcellular
distribution in the cell culture models. We observed calpain independent translocation of
AIF to the nucleus, suggesting lack of necessity for calpains in AIF processing and
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redistribution. Hence corroborating the finding in chapter 1 and suggesting that AIF
processing, release and subsequent nuclear translocation could happen by more than
one means. Chapter 5 of this dissertation provides evidence of mitochondrial !-calpain
regulation by establishing the localization of, calpain inhibitor, calpastatin in the
mitochondrial intermembrane space. Finally this dissertation provides information
regarding the mechanism of calpastatin import into the mitochondria and ascribes
mitochondrial targeting sequence to the N-terminus of the XL domain of calpastatin.
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Fig 1.1 Structure of calpains. A cartoon representation of the biochemical structure of
calpain large catalytic subunit and calpain small regulatory subunit. The 80 kD calpain
large catalytic subunit is comprised of four domains namely Domain I, II, III, and IV.
Domain I is 18 amino acids long, Domain II has the catalytic triad and is further
subdivided into Domain IIa, having the cysteine residue at position 105, and Domain IIb,
having the histidine and asparagines residues at positions 262 and 286 respectively,
Domain III has a 17 amino acids long linker domain called T domain and Domain IV has
the five calcium binding EF-hands (black vertical bars). The 28 kD calpain small
regulatory subunit is comprised of two domains namely Domain V and Domain VI.
Domain V is glycine rich (black vertical bar) and Domain VI has the five calcium binding
EF-hands (black vertical bars). Abbreviations: N-terminal-Amino terminal, C-terminalCarboxy terminal, T-17 amino acid linker domain, aa-amino acids, Cys-Cysteine, HisHistidine, Asn-Asparagine, kD-Kilodalton.
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Fig 1.1 Structure of calpains
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Fig 1.2 Apoptosis-inducing factor structure and isoforms. Schematic diagram of the
apoptosis-inducing factor structure and isoforms, demonstrating location of
oxidoreductase domain (FAD and NADH binding domains), mitochondrial localization
signals, and nuclear localization signal. Apoptosis-inducing factor (AIF) contains two
mitochondrial localization signals, a nuclear localization signal and an oxidoreductase
domain. There are three states in which AIF can exist in a cell. Precursor AIF (67 kD) is
full length, 613 amino acids long and is localized to the cytosol, mature AIF (62 kD)
starts at amino acid position 55 and is anchored to the mitochondrial inner membrane
and truncated AIF (tAIF-57 kD) begins at amino acid position 103 and is localized to the
nucleus. There are five major isoforms of AIF. Full length AIF (Precursor AIF), encoded
by exons 1-16 on X chromosome, is 613 amino acids long and is localized to the cytosol.
AIF-exB, encoded by exons 1-16 but uses exon 2b instead of exon 2, is 609 amino acids
long and is localized to the mitochondria. AIF-Short, encoded by exons 10-16, is 261
amino acids long and localizes to the cytosol. AIF-Short2, encoded by exons 1-9b
(alternative splicing of exon 9), is 324 amino acids long and localizes to the
mitochondria. AIF-Short3 is encoded by exons 1-9b (alternative splicing of exon 2 and 9)
and is 237 amino acids long. The nomenclature, exon composition, and subcellular
locations are listed in the periphery. The residues encompassing each domain are listed
below each segment. Abbreviations: N-terminal-Amino terminal, C-terminal-Carboxy
terminal, AIF-Apoptosis-inducing factor, MLS -Mitochondrial localization signal, NLSNuclear localization signal, FAD-Flavin adenine dinucleotide, NADH-Nicotinamide
adenine dinucleotide, Met-Methionine, Ala-Alanine, Gly-Glycine, kD-Kilodalton.
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Fig 1.2 Apoptosis-inducing factor structure and isoforms
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Fig 1.3 Mitochondria - Nucleus cross talk via apoptosis-inducing factor. A schematic of
cross talk between mitochondria and nucleus via AIF. Precursor AIF (67 kD) after
synthesis in the cytosol is imported into the mitochondria due to dual mitochondrial
localization signals. Following import, mitochondrial localization signal is processed by a
mitochondrial peptidase and mature AIF (62 kD) is inserted into the mitochondrial inner
membrane. Mature AIF (62 kD) participates in maintaining mitochondrial structure and
function. Under certain cellular death signals mature AIF is processed by an unknown
protease, near its N-terminus, to be released from the inner mitochondrial membrane
attachment as truncated AIF (tAIF-57 kD). This free floating tAIF, due to a nuclear
localization signal, then migrates out of the mitochondria to the cytosol and finally to the
nucleus. The release of tAIF is inhibited by over expression of BCL-2 and the
translocation of tAIF to the nucleus is inhibited by the over expression of HSP70. Inside
the nucleus tAIF induces large scale (50 kB) DNA fragmentation and caspaseindependent cell death. Abbreviations: ER-Endoplasmic reticulum, SERCASarcoplasmic endoplasmic reticulum Ca+2-ATPase, IP3R-Inositol triphosphate receptor,
AIF-Apoptosis-inducing factor, MTS-Mitochondrial targeting sequence, IMM-Inner
mitochondrial membrane, OMM-Outer mitochondrial membrane, IMS-Intermembrane
space, VDAC-Voltage dependent anion channel, tAIF-Truncated AIF.
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Fig 1.3 Mitochondria - Nucleus cross talk via apoptosis-inducing factor

26

Fig 1.4 Calpastatin structure and isoforms. A representative diagram of calpastatin
structure and isoforms, demonstrating the location of various domains and subdomains.
Calpastatin consists of six domains - XL, L, and four inhibitory repeats. Each inhibitory
repeat domain has three sub domains namely A, B, and C (black vertical bars). The
residues encompassing each domain are listed below each segment. There are several
isoforms of calpastatin, due to alternate splicing, exon skipping, or variable usage of
promoters. The molecular weights of the various isoforms are listed in the periphery and
the numbers in each segment represent the exon composition of that particular domain.
Abbreviations: N-terminal-Amino terminal, C-terminal-Carboxy terminal, kD-Kilodalton.
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Fig 1.4 Calpastatin structure and isoforms
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Chapter Two
Materials and Methods
“Historical methodology, as I see it, is a product of common sense applied to
circumstances.” - Samuel E. Morison

Reagents used
Chemicals and reagents were obtained from Sigma Chemical (St. Louis, MO)
unless otherwise noted. PD150606, CA-074 and human erythrocyte calpastatin were
from Calbiochem. Potassium chloride, Glycine and Tris-base were obtained from Fisher
Scientific. Acrylamide, Bis, Nitrocellulose, Molecular weight standards, Bromophenol
blue and Tween-20 were from Bio-Rad. Complete EDTA free protease inhibitor cocktail
tablets were purchased from Roche. Cell culture reagents including minimal essential
medium (MEM), HBSS, B27, Neurobasal medium, L-glutamine, Penstrep (penicillin–
streptomycin), and 0.05% Trypsin - EDTA were purchased from Invitrogen (Gibco). Fetal
bovine serum was purchased from Atlanta Biologicals. Lipofectamine - 2000 was from
Invitrogen. Bicinchoninic acid (BCA) kit was purchased from Pierce. Percoll was
purchased through Amersham Biosciences. Alexa flour 488 secondary antibodies (cat.
no. A31620 ; 1:250) for immunocytochemistry, Hoechst stain and Mitotracker red were
from Molecular Probes. Calpain 1 domain III monoclonal antibody was from Calbiochem
(cat. no. 208728 ; 1:2000). A polyclonal antibody against the N-terminus of calpain 1 was
produced by Triple Point Biologics and purchased through Abcam (cat. no. ab28257 ;
1:2000). AIF monoclonal antibody was from Santa cruz biotechnology (E-1 clone ; cat.
no. sc-13116 ; 1:1000 for western blot and 1:50 for ICC), Mitochondrial HSP70
(mHSP70) antibody was from Affinity Bioreagents (cat. no. MA3-028 ; 1:10000), Spectrin
antibody was from Millipore (cat. no. MAB1622 ; 1:1000), and Calpastatin antibody was
from Chemicon (cat. no. MAB3084 ; 1:1000). Secondary antibodies for western blots
were IRDye 800 CW conjugated affinity purified anti-rabbit (cat. no. 611-131-122;
1:5000) or anti-mouse (cat. no. 610-131-121; 1:5000) IgG (H and L) from Rockland
(Gilbertsville, PA). Rat full-length calpastatin clone was from Open Biosystems, plasmid
WPXL was from Addgene. Phusion high fidelity PCR master mix with GC buffer was
from New England Biolabs. QIAquick gel extraction kit and High Speed plasmid maxi
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prep kit were from Qiagen. T4 ligation kit was from Invitrogen. All animals were obtained
from Harlan (Indianapolis, IN).

Mitochondrial isolation
All experimental protocols involving animals were approved by the University of
Kentucky Animal Use and Care Committee. Adult male Sprague–Dawley rats, weighing
approximately 250 g, aged eight to twelve weeks, housed three per cage in the Division
of Laboratory Animal Resources (DLAR) at the UK Medical Center accredited by
AAALC, maintained on a 12 h light/12 h dark cycle were used in all experiments. All
animals were fed a balanced diet ad libitum. The rats were anesthetized using carbon
dioxide. Mitochondria were isolated from rat cerebral cortex as described previously
(Brown et al., 2006b) based on method A of Sims (Sims, 1990) with slight modifications.
Briefly, following CO2 asphyxiation animals were decapitated, their brains were quickly
removed and the cortices were dissected. Cortical tissue was placed in ice cold
mitochondrial isolation buffer (MIB - 75 mM Sucrose, 215 mM Mannitol, 1 mM EGTA,
0.1% BSA, 20 mM HEPES, pH adjusted to 7.2 using KOH). Cortical tissues were placed
into a cold glass dounce homogenizer and homogenized with six strokes. A solution
consisting of equal amounts of 30% Percoll (v/v) and sample, for a final Percoll
concentration of 15%, was placed on a discontinuous gradient of 24% and 40% Percoll.
The density gradients were centrifuged for 10 min at 30,400 g, 4 °C in fixed angle SE-12
rotors. The fraction at 24 - 40% interface which contained the non-synaptic brain
mitochondria was removed, placed into separate tubes, and diluted with MIB. The
samples were then centrifuged at 16,700 g, 4 °C for 15 min. The supernatant was
removed and the pellet was resuspended in MIB without EGTA and BSA. It was washed
with the same buffer and centrifuged again at 11,000 g, 4 °C for 10 min. The resultant
pellet was resuspended in 1 ml of MIB without EGTA and BSA, and centrifuged at
10,000 g, 4 °C for 10 min. The final mitochondrial pellets were stored on ice.
Rat liver mitochondria were isolated using combination of differential and Percoll
discontinuous density gradient methods. Following CO2 asphyxiation, the right lateral
lobe of liver was dissected out, placed in MIB. Tissue was homogenized by 6 strokes at
500 rpm, centrifuged at 800 g, 4 °C for 10 min. The supernatant was centrifuged at
10,000 g, 4 °C for 10 min and the pellets resuspended in MIB. Pellets were
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homogenized in the glass dounce homogenizer, and centrifuged at 3000 g, 4 °C for 5
min. The supernatant was then centrifuged at 10,000 g, 4 °C for 10 min and the pellet
was resuspended in MIB, centrifuged at 9000 g, 4 °C for 10 min and resuspended the
pellet in MIB. The mitochondria were then enriched using a discontinuous Percoll density
gradient as described for brain mitochondrial isolation.
Mitochondria from SH-SY5Y cells were isolated as described previously (Garcia
et al., 2005; Badugu et al., 2008) as per Sims method B (Sims, 1990). Briefly, SH-SY5Y
cells were trypsinized and centrifuged at 2000 rpm at 4 °C for 10 min. The pellet was
resuspended in MIB, incubated on ice for 10 min and then dounce homogenized by 15
strokes. A solution consisting of equal amounts of 24% Percoll (v/v) and sample, for a
final Percoll concentration of 12%, was placed on a discontinuous gradient of 26% and
40% Percoll. The density gradients were centrifuged for 10 min at 30,400 g, 4 °C in fixed
angle SE-12 rotors. The fraction at 26 - 40% interface which contained the mitochondria
was removed, placed into separate tubes, and diluted with MIB. The samples were then
centrifuged at 16,700 g, 4 °C for 15 min. The supernatant was removed and the pellet
was resuspended in MIB. It was washed with the same buffer and centrifuged again at
11,000 g, 4 °C for 10 min. The resultant pellet was resuspended in 1 ml of MIB, and
centrifuged at 10,000 g, 4 °C for 10 min. The final mitochondrial pellets were stored on
ice.

Mitochondrial swelling assay
Mitochondrial swelling was estimated based on changes in light scattering at 540
nm, measured in a Biotek Synergy HT microplate reader (Biotek instruments, Winooski,
VT). Isolated mitochondria from the rat cerebral cortex or rat liver (1 mg/ml) were
resuspended in the respiration buffer (125 mM KCl, 2 mM MgCl2, 20 mM HEPES, 2.5
mM KH2PO4, pH 7.2) with 5 mM pyruvate, 2.5 mM malate and 150 µM ADP. Swelling
was estimated after 15 min of incubation with atractyloside (Atr) or alamethicin (Ala), or
without treatment. Mitochondrial swelling is represented by decreased absorbance.
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Incubation of mitochondria with atractyloside, alamethicin, and calcium
BCA protein assay was done on mitochondria from all sources. Mitochondria (1
mg/ml, protein content determined using Pierce BCA method) were resuspended in
respiration buffer with pyruvate, malate, and ADP. Samples were incubated in the
presence or absence of inhibitors including MDL28170 (20 µM), PD150606 (50 µM),
human erythrocyte calpastatin (20 IU) at 4 °C for 15 min. Mitochondria were then
incubated with either 5 mM atractyloside (Atr) for 30 min at 30 °C or with 15 µM
alamethicin (Alm) for 15 min at 37 °C. This was followed by centrifugation at 13,400 g for
30 min at 4 °C. The supernatants and pellets were collected, 3X sample buffer (0.5 M
Tris-pH 6.8, SDS, Glycerol, !-mercaptoethanol, 1% Bromophenol blue) was added.
Samples were boiled at 100 °C for 10 min and were stored at "80 °C prior to western
blot analysis.
SH-SY5Y isolated mitochondria were resuspended in calpain activity buffer (20
mM Tris–HCl, 1 mM EDTA, 100 mM KCl, 0.1% !-mercaptoethanol, pH 7.5) at 2 mg/ml.
Calcium chloride (0, 0.5 or 5 mM) was added and the suspension was incubated for 2 h
at room temperature with shaking. Solubilized mitochondria were treated with 0.2%
Triton X-100 prior to incubation with CaCl2. Following incubation, 3X sample buffer was
added. Samples were boiled at 100 °C for 10 min and were stored at "80 °C.

Submitochondrial fractionation
Percoll-enriched mitochondria from rat brain cerebral cortex or SH-SY5Y cells
were incubated in a hypotonic buffer (10 mM HEPES/KOH, pH 7.4) for 20 min on ice to
rupture the outer mitochondrial membrane. 2X MIB was added after incubation to restore
the isotonic conditions. It was centrifuged at 1900 g, 4 °C for 15 min on a tabletop
centrifuge to obtain the mitoplast pellet. The supernatant was further centrifuged at
35,000 g (19,200 rpm in SW 55Ti rotors), 4 °C for 15 min to yield intermembrane space
contents in the supernatant and outer and inner mitochondrial membrane fragments in
the pellet. 3X sample buffer was added to the various fractions, boiled at 100 °C for 10
min, resolved by SDS-PAGE and analyzed by western blotting for calpastatin.
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Proteinase K treatment of mitochondria and mitoplasts
Percoll-enriched mitochondria from rat brain cerebral cortex or SH-SY5Y cells or
hypotonically prepared mitoplasts from SH-SY5Y cells (at 2-4 mg/ml) were resuspended
in MIB, pH 8.0, and treated with proteinase K (50 !g/ml) at 37 °C for 30 min. Proteinase
K activity was terminated by adding 2 mM PMSF followed by incubation on ice for 10
min. Mitochondria or mitoplasts were centrifuged at 13,000 g, 4 °C for 10 min. Pellets
were resuspended in MIB and analyzed by SDS-PAGE and western blotting. Proteinase
K activity was confirmed by incubating 0.2% Triton-X 100 solubilized mitochondria or
mitoplasts with proteinase K (50 !g/ml), centrifuged at 13,000 g, 4 °C for 10 min and
supernatants were resolved on SDS-PAGE gel and analyzed by western blotting.

Primary hippocampal cultures/ Cell culture
Primary hippocampal cultures from rats were prepared as described previously
(Pang and Geddes, 1997; Sengoku et al., 2004) based on procedure of Brewer and
colleagues (Brewer et al., 1993) from E18 pups, with slight modifications. The dam was
euthanized by CO2 asphyxiation, fetuses were removed aseptically, the brain was
removed, and hippocampi were dissected and digested in HBSS containing 0.25%
Trypsin for 15 min at room temperature. The hippocampi were washed in HBSS and
incubated with Trypsin inhibitor (1 mg/ml) for 5 min. Tissue was dissociated by trituration
in HBSS with a fire-polished pasteur pipette. Cells were counted using trypan blue
staining and seeded at 0.3 million/35mm2 into poly-D-lysine (50 !g/ml) coated glass
bottom dishes containing neurobasal medium with glutamate. On next day half of the
medium was replaced by neurobasal medium with B27 and glutamine. The neurons
were maintained in a humidified 5% CO2 incubator at 37 °C for 12 days. Neuronal
cultures were incubated with 20 !M MDL28170 for 1 h before the treatments. NMDA
was added at 100 !M in the presence of 10 !M glycine and A23187 was added at 10 !M
concentration for the indicated period of times respectively.
SH-SY5Y cells were obtained from American Type Culture Collection (Manassas,
VA) and propagated in MEM with non-essential amino acids, 10% fetal bovine serum,
1% penicillin–streptomycin until 80% confluent. SH-SY5Y cells were used for
mitochondrial isolation or were treated with 100 !M Thapsigargin for indicated time
points. Following treatments, primary hippocampal neurons or SH-SY5Y cells were
either lysed in lysis buffer (62.5 mM Tris, 6M Urea, 10% Glycerol, 2% SDS, pH 6.8)
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sonicated for subsequent protein assay and western blot analysis or were fixed for
immunocytochemistry.

Immunocytochemistry
Immunocytochemistry was performed to evaluate AIF subcellular localization in
the primary hippocampal neurons or SH-SY5Y cells. Mitochondria of these cells were
labeled using mitotracker red 580 nM (1 mM). Mitotracker red was added to the culture
medium for 15 min at 37 °C to label the mitochondria. Excess mitotracker was removed
by washing 2X with the medium. Following treatments and mitochondrial labeling, cells
were rinsed 2X in 1X PBS, fixed in 4% paraformaldehyde for 30 min, and rinsed again
3X in 1X PBS. Cells were then permeabilized in 0.2% Triton X-100 in 1X PBS for 5 min,
washed 2X in 1X PBS followed by blocking in normal horse serum in 1X PBS for 30 min.
Cells were washed in 1X PBS and then incubated in AIF primary antibody solution made
in 1X PBS / horse serum for overnight. Next day cells were washed in 1X PBS and
incubated for one hour in a species-appropriate secondary antibody conjugated with
Alexa Flour 488 in 1X PBS in dark. Thereafter cells were washed in 1X PBS, followed by
incubation in Hoechst 3342 (1:10,000 in 1X PBS) for 15 min to stain the nuclei. Excess
stain was removed by 2X washes in 1X PBS. Finally imaging was performed on the
Olympus DSU (Spinning disc confocal) IX81 motorized inverted microscope, with 2
digital cameras - EM-CCD Hamamatsu, at 100X oil objective in green, blue and red
channels and Z stacks captured at a depth of 0.5 to 1.0 !M each through the cells. This
system is equipped with a 473 laser. The software used was Slidebook version 4.2
including a Deconvolution/Volume rendering module.

In situ Calpain activity assay
For in situ detection of calpain activity 20 !M t-Boc (7-amino-4chloromethylcoumarin, t-BOC-L-leucyl-L-methionine amide (CMAC, t-BOC-Leu-Met))
(Invitrogen) was added to the cells for 30 min. Unbound t-Boc was washed off before the
thapsigargin treatment. Following treatment, cells were washed 2X with 1X PBS and
imaging was done on fluorescent microscope at 330 nM absorbance and 403 nM
emission wavelengths (Glading et al., 2000; Xu and Deng, 2006b, a).
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Construction of 1-30XLDCAST-pWPXL
The N-terminus 30 amino acid sequence of the XL domain of calpastatin was
PCR amplified from the rat calpastatin vector obtained from Open Biosystems - clone Id
7324026, accession no. BC 091239, catalog no. MRN1768-98079946,!using forward
primer 5’-ATGTCCCCGGCCCGGCCCGAA-3’ and reverse primer 5’GCATACGCGTTTCTTTTCATTAACATGC-3’ having Mlu I site. Phusion high fidelity
PCR mastermix with GC buffer was used for PCR reaction. Reaction conditions were –
98 °C 30s, 36 cycles at 98 °C 10s, 70 °C 10s, 72 °C 15s, and then 72 °C 5 min. PCR
fragment was extracted from 2% agarose gel using QIAquick gel extraction kit, as per
manufacturer’s instructions. The 1-30XL domain fragment of calpastatin (1-30XLDCAST)
was digested with Mlu I and pWPXL vector was digested with Pme I and Mlu I. Vector
and fragment ligation was done overnight using Invitrogen T4 ligation kit. DH5!
competent cells were used for transformation and miniprep was selected using Nhe I
digestion. Plasmid DNA of 1-30XLDCAST-pWPXL was extracted using QIAquick kit.
Lipofectamine - 2000 transfection reagent was used as per the manufacturer’s protocol
for transfecting 1 "g of 1-30XLDCAST-pWPXL vector or pWPXL vector. SH-SY5Y cells
were used for the live cell imaging for 1-30XLDCAST-pWPXL or pWPXL localization. 24
h post transfection cells were visualized on the previously mentioned microscope
(Olympus DSU (Spinning disc confocal) IX81 motorized inverted microscope). After GFP
imaging, mitotracker red 580 nM (1 mM) was added to the culture medium for 15 min at
37 °C to label the mitochondria. Following incubation cells were washed twice with the
media and imaged as mentioned above for both GFP and mitotracker staining.

Western blotting
Equal amount of protein, along with molecular weight markers, were separated
by SDS-PAGE on 10% or 6.5% Tris–glycine polyacrylamide gels. The proteins were
transferred to 0.45 µM nitrocellulose membranes (Bio-Rad) by electrophoresis, and
membranes were incubated in 5% nonfat dry milk powder in TBS (50 mM Tris, NaCl
0.14 M, pH7.5). Membranes were incubated with primary antibodies overnight in 5%
nonfat milk and TTBS (TBS, 0.05% tween-20, pH 7.5). After three washes for 20 min
each in TTBS, membranes were incubated with the species-appropriate secondary
antibody for 1 h at room temperature in the dark. The membranes were washed 3X in
TTBS, scanned using a Li-Cor Biosciences Odyssey infrared imaging system (Lincoln,
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Nebraska, USA) and band intensity was quantified using Odyssey infrared imaging
system application software version 1.2.

Statistics
Statistical calculations were performed using Statview software. Analysis
consisted of Student's unpaired t-test or ANOVA followed by Fisher's LSD post hoc test
for multiple comparisons. Data is expressed as mean ±S.E.M. from at least three
independent experiments. P of <0.05 was considered significant.

Copyright © Aashish Joshi 2009
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Chapter Three
Mitochondrial !-calpain is not involved in the processing of apoptosis-inducing
factor
Aashish Joshi, Vimala Bondada, and James W. Geddes
“There is nothing like looking, if you want to find something. You certainly usually find
something, if you look, but it is not always quite the something you were after.” - J.R.R.
Tolkien
Introduction
Cell death mechanisms can be broadly classified as programmed and nonprogrammed, with programmed cell death being further subdivided into caspasedependent and caspase-independent mechanisms (Kroemer and Martin, 2005; Boujrad
et al., 2007). Caspase-independent cell death (CICD) occurs following the cleavage and
release of apoptosis-inducing factor (AIF) from mitochondria and the subsequent
translocation of AIF to the nucleus, resulting in DNA fragmentation (Cregan et al., 2002;
Boujrad et al., 2007). CICD is of particular importance in adult neurodegeneration (Stoka
et al., 2006). CICD and AIF translocation can be induced by DNA damage resulting in
the activation of poly (ADP-ribose) polymerase-1 (PARP-1) (Wang et al., 2009a) or by
excessive mitochondrial Ca2+ uptake, the focus of the present study.
The N-terminus of mature 62 kD AIF is anchored in the inner mitochondrial
membrane, with the remainder of the protein projecting into the intermembrane space.
AIF release requires proteolysis near the N-terminus to generate a 57 kD fragment
(Otera et al., 2005). µ-Calpain is an attractive candidate for the protease responsible for
this cleavage (Liou et al., 2005; Polster et al., 2005). µ-Calpain composed of the calpain
1 large subunit and calpain small subunit-1, cleaves the 62 kD AIF to a 57 kD fragment
(Polster et al., 2005). Calpain inhibitors such as calpeptin block the release of AIF from
rat and mouse liver mitochondria following opening of the mitochondrial permeability
transition pore by Ca2+ or Atr (Polster et al., 2005; Yuste et al., 2005). One difficulty with
the above hypothesis is that µ-calpain was thought to be a cytosolic enzyme, which
would require permeabilization of the outer mitochondrial membrane to gain access to
AIF. The recent localization of µ-calpain to the mitochondrial intermembrane space
avoids this issue and provides further support for the putative role of µ-calpain in the
truncation of AIF (Garcia et al., 2005; Cao et al., 2007; Badugu et al., 2008; Norberg et
al., 2008).
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Mitochondria have a finite capacity for Ca2+ uptake, which when exceeded results
in the opening of a non-specific mitochondrial permeability transition pore (mPTP) in the
inner mitochondrial membrane. mPTP opening allows the passage of molecules less
than 1.5 kD and results in the loss of mitochondrial membrane potential, release of Ca2+
from the mitochondrial matrix, mitochondrial swelling, and rupture of the outer
mitochondrial membrane (Bernardi and Rasola, 2007). The localization of µ-calpain to
the intermembrane space positions this protease to be activated by Ca2+ released
following mPTP opening, and in the same subcellular compartment as the C-terminal
region of AIF (Fig 3.1). In this study we evaluated the hypothesis that AIF processing
and release is mediated by mitochondrial µ-calpain.
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Results
Atractyloside-induced AIF release from isolated liver mitochondria
Isolated rat liver mitochondria were monitored for swelling at 540 nM following
treatment with atractyloside (Atr) and alamethicin (Alm). Atr is a ligand for the adenine
nucleotide translocase, and promotes formation of the permeability transition pore
(Vieira et al., 2000). Alm, a peptide antibiotic, forms artificial channels in biological
membranes (Ritov et al., 1992; Brustovetsky et al., 2002). Both drugs induced significant
mitochondrial swelling and AIF release, although AIF release was more pronounced with
Atr (Fig 3.2 A, B and C). AIF released into the supernatant fraction was of a slightly
lower mol. wt. than AIF in the mitochondrial pellets, consistent with the requirement for
AIF truncation prior to mitochondrial release and nuclear translocation (Otera et al.,
2005). Atr did not induce release of matrix protein mHSP70 in the supernatant showing
that Atr induced AIF release is a specific phenomenon (Fig 3.2 D).

Atractyloside did not induce AIF release from isolated brain mitochondria
As with liver mitochondria, both Atr and Alm induced swelling in isolated nonsynaptic rat brain mitochondria (Fig 3.3 A). However, in contrast to rat liver mitochondria,
Atr failed to induce AIF release from the rat brain mitochondria (Fig 3.3 B). The lack of
response to Atr was also observed in synaptic rat brain mitochondria (results not
shown). Incubation of the rat brain mitochondria with Alm did result in release of AIF into
the supernatant fraction (Fig 3.3 C), similar to results obtained with rat liver
mitochondria.

Atractyloside-induced AIF release is inhibited by cysteine protease inhibitor MDL28170
and cathepsin inhibitor CA-074
Previous studies have suggested the involvement of a calpain or another
cysteine protease in AIF processing and release (Polster et al., 2005; Yuste et al., 2005).
Preincubation of isolated liver mitochondria with 20 µM MDL28170 (carbobenzoxyvalylphenylalanial; calpain inhibitor III), inhibited Atr-induced AIF release from the rat
liver mitochondria (Fig 3.4). However, this drug inhibits both calpains and other cysteine
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proteases including cathepsin B (Wang, 1999). We therefore examined more specific
calpain inhibitors including PD150606 (Wang et al., 1996) and calpastatin (Wendt et al.,
2004). Both failed to prevent AIF release from rat liver mitochondria (Fig 3.4). We also
examined the effect of cathepsin inhibitor CA-074 on Atr-induced AIF release.
Preincubation of the isolated liver mitochondria with CA-074 significantly reduced the
Atr-induced AIF release from the rat liver mitochondria (Fig 3.5). Moreover, µ-calpain
immunoreactivity was difficult to detect in the mitochondria-enriched fraction from rat
liver (Fig 3.6), in contrast to mitochondrial fractions from rat cerebral cortex (Fig 3.6).

Calpain activation is not sufficient for AIF release
In mitochondria isolated from rat cerebral cortex, incubation with various levels of
Ca2+ up to 5 mM did not result in µ-calpain activation or AIF release (results not shown).
One possible explanation is that the µ-calpain may have been activated during the
euthanasia, brain removal, and mitochondrial isolation procedure (Garcia et al., 2005),
making subsequent activation difficult. To further investigate the possible role of
mitochondrial µ-calpain in AIF release, we utilized mitochondria from SH-SY5Y
neuroblastoma cells, which we previously demonstrated to contain µ-calpain, and in
which the calpain 1 immunoreactivity is evident as a single 80 kD band (Garcia et al.,
2005; Badugu et al., 2008). Incubation of SH-SY5Y mitochondria with 5 mM, but not 0.5
mM, Ca2+ resulted in a lower mol. wt. calpain-1 immunoreactive band (Fig 3.7), indicative
of autoproteolysis and calpain activation (Cong et al., 1989; Li et al., 2004). Calpain
autolysis was also observed using an antibody specific for the N-terminus of calpain 1,
which shows a loss in immunoreactivity following µ-calpain activation (Fig 3.7). Under
these conditions of calpain activation, we did not detect increased AIF proteolysis in the
mitochondrial fraction (Fig 3.7). Following solubilization of the mitochondria, AIF was
processed to a smaller mol. wt. fragment following incubation with 5 mM Ca2+ (Fig 3.7,
lower band indicated by arrow). MDL28170 (20 µM) inhibited the Ca2+-induced calpain
activation in both intact and solubilized mitochondria, and attenuated the intensity of the
lower mol. wt. AIF band following Ca2+ incubation in the Triton-solubilized mitochondria
(Fig 3.7).
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Fig 3.1 Mitochondrial permeability transition. The components and regulation of the
mitochondrial permeability transition pore are not fully understood, the following is a
working model. In response to elevated Ca2+ in the mitochondrial matrix (and promoted
by oxidative stress and reduced adenine nucleotides), Cyclophilin D (CypD) induces a
conformational change in adenine nucleotide translocase (ANT), resulting in the opening
of a non-specific channel, the mPTP. The voltage-dependent anion channel (VDAC) in
the outer mitochondrial membrane may also contribute to pore opening. This results in a
rapid efflux of Ca2+ and other small solutes (<1500 Da) from the matrix into the
mitochondrial intermembrane space and cytosol, matrix swelling, mitochondrial
depolarization, and release of death-effecter proteins including apoptosis-inducing factor
(AIF). µ-Calpain is also located in the mitochondrial intermembrane space where it is
hypothesized to be activated following mPTP opening and to cleave AIF.

41

Fig 3.1 Mitochondrial permeability transition
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Fig 3.2 Atractyloside and Alamethicin induce AIF release from rat liver mitochondria.
Isolated rat liver mitochondria were incubated with 5 mM Atr for 30 min at 30 °C or 15
µM Alm for 30 min at 37 °C in the KCl-based mitochondrial respiration buffer with
pyruvate, malate and ADP. (A) The decrease in absorbance (540 nm) of the
mitochondrial suspension indicates that both Atr and Alm induced swelling of the rat liver
mitochondria. (B) Incubation with Atr resulted in cleavage of 62 kD AIF from the
mitochondrial pellet into a 57 kD band released into the supernatant fraction. (C)
Incubation of the rat liver mitochondria with Alm also resulted in the release of truncated
AIF from the mitochondrial pellet into the supernatant fraction. (D) Incubation with Atr did
not release matrix protein mHSP70 into the supernatant fraction. Representative
western blots probed for AIF or mHSP70 are shown. The data are from at least three
independent experiments, represented as mean ±S.E.M, * indicates P<0.05, ** indicates
P<0.01, NS indicates that differences were not significant at P=0.05 as per student’s
unpaired t-test or ANOVA followed by Fisher’s LSD post hoc test for multiple
comparisons, relative to control. Antibodies used: AIF (E-1 clone ; Santa cruz
biotechnology cat. no. sc-13116 ; 1:1000), mHSP70 (Affinity Bioreagents cat. no. MA3028 ; 1:10000). Abbreviations: Cnt-Control, Atr-Atractyloside, Alm-Alamethicin.
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Fig 3.2 Atractyloside and Alamethicin induce AIF release from rat liver mitochondria.
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Fig 3.3 AIF is not released from rat brain mitochondria following incubation with
Atractyloside. Mitochondria enriched from the cerebral cortex of the rat brain were
incubated with 5 mM Atr for 30 min at 30 °C or 15 µM Alm for 30 min at 37 °C in the KClbased mitochondrial respiration buffer with pyruvate, malate and ADP. (A) The decrease
in absorbance (540 nm) of the mitochondrial suspension indicates that both Atr and Alm
induced swelling of the rat brain mitochondria. (B) Incubation with Atr did not result in the
cleavage or release of AIF from the mitochondrial pellet into the supernatant fraction. (C)
Incubation of the rat brain mitochondria with Alm resulted in the release of AIF from the
mitochondrial pellet into the supernatant fraction. Representative western blots probed
for AIF are shown. The data are from at least three independent experiments,
represented as mean ±S.E.M, * indicates P<0.05, NS indicates that differences were not
significant at P=0.05 as per student’s unpaired t-test or ANOVA followed by Fisher’s LSD
post hoc test for multiple comparisons, relative to control. Antibodies used: AIF (E-1
clone ; Santa cruz biotechnology cat. no. sc-13116 ; 1:1000). Abbreviations: Cnt-Control,
Atr-Atractyloside, Alm-Alamethicin.
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Fig 3.3 AIF is not released from rat brain mitochondria following incubation with
Atractyloside.
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Fig 3.4 Atractyloside-induced AIF release in rat liver mitochondria was inhibited by
cysteine protease inhibitor MDL28170 but not by specific calpain inhibitors PD150606 or
human erythrocyte calpastatin. Isolated rat liver mitochondria were incubated with 20 µM
MDL28170 (MDL), 50 µM PD150606 (PD), or 20 IU human erythrocyte calpastatin
(CAST) at 4 °C for 15 min on ice. The mitochondria were then incubated with 5 mM Atr
for 30 min at 30 °C in the KCl-based mitochondrial respiration buffer with pyruvate,
malate and ADP. Supernatants (A) and pellets (B) were separated, subjected to SDSPAGE and western blotting for AIF. MDL28170, but not PD150606 or CAST inhibited the
release of AIF from the mitochondrial fraction. Representative western blots probed for
AIF are shown. Data are from at least three independent experiments, represented as
mean ±S.E.M. * indicates P<0.05, ** indicates P<0.01, NS indicates that differences
were not significant at P=0.05 as per ANOVA followed by Fisher’s LSD post hoc test for
multiple comparisons, relative to Atr. Antibodies used: AIF (E-1 clone ; Santa cruz
biotechnology cat. no. sc-13116 ; 1:1000). Abbreviations: Cnt-Control, Atr-Atractyloside,
MDL-MDL28170, PD-PD150606, CAST-Calpastatin.

47

Fig 3.4 Atractyloside-induced AIF release in rat liver mitochondria was inhibited by
cysteine protease inhibitor MDL28170 but not by specific calpain inhibitors PD150606 or
human erythrocyte calpastatin.
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Fig 3.5 Atractyloside-induced AIF release in rat liver mitochondria was significantly
reduced by cathepsin inhibitor CA-074. Isolated rat liver mitochondria were incubated
with 20 µM MDL28170 (MDL) or 20 !M CA-074 (CA) at 4 °C for 15 min on ice. The
mitochondria were then incubated with 5 mM Atr for 30 min at 30 °C in the KCl-based
mitochondrial respiration buffer with pyruvate, malate and ADP. Supernatants (A) and
pellets (B) were separated, subjected to SDS-PAGE and western blotting for AIF.
MDL28170 completely inhibited Atr-induced AIF release and CA-074 also significantly
reduced the Atr-induced release of AIF from the mitochondrial fraction. Representative
western blots probed for AIF are shown. Data are from at least three independent
experiments, represented as mean ±S.E.M. * indicates P<0.05 as per ANOVA followed
by Fisher’s LSD post hoc test for multiple comparisons, relative to Atr. Antibodies used:
AIF (E-1 clone ; Santa cruz biotechnology cat. no. sc-13116 ; 1:1000). Abbreviations:
Cnt-Control, Atr-Atractyloside, MDL-MDL28170, CA-CA-074.
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Fig 3.5 Atractyloside-induced AIF release in rat liver mitochondria was significantly
reduced by cathepsin inhibitor CA-074.
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Fig 3.6 Calpain-1 immunoreactivity is difficult to detect in rat liver mitochondria.
Mitochondria were isolated from rat liver and rat cerebral cortex as described in
materials and methods. The starting homogenate (H) and the final mitochondrial
enriched fraction (M) from the two tissues were subjected to SDS-PAGE and western
blotting, and probed for calpain-1 (the large subunit of µ-calpain) using an antibody
against N-terminal or for mitochondrial HSP70 (mHSP70). The results indicate an
enrichment of 80 kD calpain-1 immunoreactivity in rat brain mitochondria, but very faint
calpain-1 immunoreactivity in rat liver mitochondria. Representative western blots are
shown. Protein loaded 80 µg/lane. Antibodies used: Calpain-1 (Abcam cat. no. ab28257
; 1:2000), mHSP70 (Affinity Bioreagents cat. no. MA3-028 ; 1:10000). Abbreviations: HHomogenate, M-Mitochondrial fraction.
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Fig 3.6 Calpain-1 immunoreactivity is difficult to detect in rat liver mitochondria.
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Fig 3.7 Mitochondrial µ-calpain activation does not result in AIF cleavage in SH-SY5Y
mitochondria. Mitochondria enriched from SH-SY5Y cells were treated with 0.5 or 5 mM
CaCl2, with or without Triton X-100 solubilization, and in the presence or absence of 20
µM MDL28170, in calpain activity buffer for 2 h at room temperature. Proteins were
resolved by SDS-PAGE and western blotting was performed using antibodies against
calpain-1 (anti-domain III and anti-N-terminus). In non-solubilized mitochondria,
incubation with 5 mM, but not 0.5 mM, CaCl2 resulted in calpain activation as indicated
by autolysis of the N-terminal, resulting in a lower mol. wt. calpain-1 band and loss of Nterminal calpain-1 immunoreactivity. These conditions did not, however, result in AIF
cleavage. In mitochondria solubilized with 0.2% Triton X-100, 5 mM CaCl2, resulted in
both calpain activation and AIF cleavage. The lower mol. wt. AIF band is identified by an
arrow in the lower panel. MDL28170 (20 µM) inhibited both the calpain-1 autolysis and
AIF truncation induced by 5 mM Ca2+. Representative western blots are shown.
Antibodies used: Calpain-1 (Calbiochem cat. no. 208728 ; 1:2000), Calpain-1 N terminal
(Abcam cat. no. ab28257 ; 1:2000), AIF (E-1 clone ; Santa cruz biotechnology cat. no.
sc-13116 ; 1:1000).
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Fig 3.7 Mitochondrial µ-calpain activation does not result in AIF cleavage in SH-SY5Y
mitochondria.
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Discussion
The results of this study do not support a role for mitochondrial µ-calpain in AIF
release. In mitochondria enriched from rat liver, Atr-induced AIF truncation and release
was inhibited by the calpain inhibitor MDL28170 but not by the more specific calpain
inhibitors PD150606 and calpastatin. Although MDL28170 was designed as a calpain
inhibitor and is widely used for this purpose, it also inhibits other cysteine proteases
including cathepsin B (Mehdi et al., 1988; Sasaki et al., 1990; Wang, 1999). Atr-induced
AIF truncation and release was significantly reduced by preincubation with cathepsin
inhibitor CA-074. In addition, it was difficult to detect µ-calpain immunoreactivity in
mitochondria enriched from rat liver. This contrasts with the enrichment of µ-calpain in
the mitochondrial fractions vs. homogenate obtained from rat cerebral cortex (Garcia et
al., 2005). Ozaki et al, (2007) were able to detect and enrich a µ-calpain like protein from
swine liver. However, they used only differential centrifugation (4500 g for 10 min) to
enrich mitochondria, in contrast to the combination of differential and discontinuous
Percoll density gradient centrifugation utilized in the present study. It is therefore
possible that at least some of the µ-calpain detected in their mitochondrial fraction
represents cytosolic µ-calpain. Together, these results argue against a role for µ-calpain
in the truncation and release of AIF from rat liver mitochondria following mPTP opening
with Atr.
For mitochondria enriched from rat brain, we were unable to induce AIF release
following incubation with either Ca2+ or Atr, although AIF release was observed following
permeabilization with Alm. We were also unable to demonstrate µ-calpain activation
under similar conditions. Several proteolytic fragments of calpain 1 are observed in
mitochondria isolated from rat brain (Garcia et al., 2005), indicative of calpain activation
prior to or during the isolation procedure which could interfere with the ability to activate
calpain in the isolated mitochondria. We therefore examined mitochondria obtained from
human SH-SY5Y neuroblastoma cells in which proteolytic calpain 1 fragments are not
observed (Garcia et al., 2005). In the SH-SY5Y mitochondria, incubation with 5 mM, but
not 0.5 mM, Ca2+ resulted in µ-calpain activation but not in AIF truncation. In Triton X100 solubilized mitochondria, 5 mM Ca2+ resulted in both µ-calpain activation and AIF
cleavage. The 5 mM Ca2+ results in Triton solubilized mitochondria are consistent with
the ability of µ-calpain to cleave AIF, but suggest that AIF and µ-calpain are spatially
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separated within intact mitochondria and that AIF is not a mitochondrial µ-calpain
substrate.
Together, these findings argue against mitochondrial µ-calpain being the
protease responsible for AIF cleavage under conditions that cause mPTP opening. In
both rat brain and liver mitochondria, permeabilization of the outer mitochondrial
membrane with Alm enabled AIF release. This suggests that a pool of truncated AIF is
available for release following outer mitochondrial membrane permeabilization by Bid or
related proteins. The requirement of outer membrane permeabilization for AIF release is
consistent with several other studies (Shalbuyeva et al., 2006; Shulga and Pastorino,
2006; Landshamer et al., 2008). However, release of AIF also requires cleavage of the
C-terminal 57 kD portion from the N-terminal anchor in the inner mitochondrial
membrane (Otera et al., 2005). The protease responsible for AIF cleavage prior to
release remains to be determined.
The ability of MDL28170, which inhibits both calpains and cysteine cathepsin
proteases, to inhibit AIF release as well as significant reduction in AIF release by
cathepsin inhibitor CA-074 suggests the possible involvement of a cysteine cathepsin,
such as cathepsin B (Yuste et al., 2005; Chaitanya and Babu, 2008). Although cathepsin
B is a lysosomal protease, an alternatively spliced variant lacking exons 2 and 3 is
targeted to mitochondria (Muntener et al., 2004). However, this splice variant is
catalytically inactive due to improper folding (Baici et al., 2006). In addition, cathepsin B
knockout does not alter AIF release induced by a DNA alkylating agent (Moubarak et al.,
2007).
Although our findings argue against the involvement of mitochondrial µ-calpain,
the results do not rule out a role for cytosolic µ-calpain in AIF processing. Cytosolic µcalpain could gain access to AIF following outer mitochondrial membrane
permeabilization. In previous studies involving isolated mitochondria, exogenous µcalpain was added to achieve mitochondrial AIF proteolysis (Liou et al., 2005; Polster et
al., 2005; Cao et al., 2007). Evidence that calpastatin overexpression and calpain 1
knockdown attenuates AIF translocation following excitotoxic insult supports a role for µcalpain, but does not distinguish between the cytosolic and mitochondrial localizations of
the protease (Cao et al., 2007). In a recent study supporting a role for mitochondrial µcalpain in AIF proteolysis, the experimental model used was digitonin permeabilized
U1810 cells incubated with Ca2+ (Norberg et al., 2008), which would not distinguish
56

between the involvement of cytosolic and mitochondrial µ-calpain. Their results did
demonstrate that blockade of mitochondrial Ca2+ uptake with ruthenium red prevented
the AIF release, although this would also inhibit mPTP opening and subsequent outer
mitochondrial membrane permeabilization.
In summary, the ability of µ-calpain to degrade mature AIF to a 57 kD fragment
(Liou et al., 2005; Polster et al., 2005), inhibition of AIF truncation and release with
specific calpain inhibitors or calpain knockdown (Cao et al., 2007; Moubarak et al., 2007;
Norberg et al., 2008), and the localization of µ-calpain to the submitochondrial
compartment in which AIF cleavage must occur would appear to provide compelling
support for the involvement of mitochondrial µ-calpain in AIF processing. However, direct
experimental support of mitochondrial µ-calpain's role in AIF truncation has been
elusive.

Copyright © Aashish Joshi 2009
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Chapter Four
Cellular studies on the role of calpain in the processing and distribution of
apoptosis-inducing factor
Aashish Joshi, Vimala Bondada, and James W. Geddes
“Nothing has such power to broaden the mind as the ability to investigate systematically
and truly all that comes under thy observation in life.”- Marcus Aurelius
Introduction
Caspase-independent cell death (CICD), implicated in various diseases and
disorders such as Parkinson’s disease, neuronal ischemia, trauma, excitotoxicity (Cao et
al., 2003; Plesnila et al., 2004; Wang et al., 2004; Liou et al., 2005; Yu et al., 2006a; Zhu
et al., 2007; Wales et al., 2008), is executed by apoptosis-inducing factor (AIF) (Cregan
et al., 2002; Boujrad et al., 2007). Mature AIF is a 62 kD flavoprotein, a bacterial
homologue oxidoreductase (Susin et al., 1999), which is anchored to the mitochondrial
inner membrane and participates in oxidative phosphorylation, mitochondrial structure
maintenance and scavenging free radicals (Klein et al., 2002; Vahsen et al., 2004; Joza
et al., 2005). Under various pathological conditions mature 62 kD AIF gets processed
into a 57 kD tAIF (Otera et al., 2005). Processing of AIF disjuncts it from inner
mitochondrial membrane attachment and exposes its nuclear localization signal (NLS).
Due to NLS, tAIF translocates from mitochondria to the nucleus and induces large scale
(50 kB) DNA fragmentation in conjunction with Endonuclease G (EndoG) (Susin et al.,
1999; Wang et al., 2002; Wang et al., 2004; Delettre et al., 2006b; Delettre et al.,
2006a).
Mature 62 kD AIF is processed at 101 amino acid position for release from inner
mitochondrial membrane attachment (Otera et al., 2005). Various proteases have been
implicated in this processing including caspases, cathepsins, or calpains. Calpains are
non-lysosomal neutral cysteine proteases (Guroff, 1964; Goll et al., 2003). Studies have
demonstrated involvement of !-calpain in the AIF processing and subsequent nuclear
translocation in MPP+ model of Parkinson’s disease (Wales et al., 2008), LL-37 peptide
induced cell death of Jurkat T cells (Mader et al., 2009), staurosporine treated U1810
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cells (Norberg et al., 2008), C44 induced cell death in HEL cells (Artus et al., 2006), and
cerebral ischemia (Cao et al., 2007).
We demonstrated in chapter 3 that mitochondrial !-calpain is not involved in the
processing of AIF in the isolated mitochondria (Joshi et al., 2009). Not all !-calpain is
mitochondrial, some !-calpain is thought to be cytosolic and calpains have ability to
translocate to membranes (Kuboki et al., 1992; Goll et al., 2003). Thus one possibility is
that cytosolic !-calpain, following outer mitochondrial membrane permeabilization, may
get translocated to the mitochondria and induce AIF processing and subsequent nuclear
translocation. The purpose of this study was to determine the role of calpain in AIF
processing and subcellular distribution. We activated calpain via three distinct
mechanisms by using NMDA or A23187 in the primary hippocampal neurons and
Thapsigargin in the SH-SY5Y human neuroblastoma cells. We report that calpain
activation does not necessarily lead to AIF processing, AIF nuclear translocation can
occur independent of calpain activity and AIF can translocate to the nucleus in full length
mature 62 kD form even without getting processed.
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Results
AIF processing is insult dependent
Calpains can be over activated by sustained calcium overload achieved using
calcium ionophore A23187 or NMDA (Prehn et al., 1994; Brorson et al., 1995; Wang,
2000). To investigate the role of calpain in AIF processing, we used NMDA or A23187
treatment model in the primary hippocampal neurons. Both drugs induced calpain
activation as demonstrated by 150 kD and 145 kD band of spectrin at all time points of
treatment (Fig 4.1). We did not detect lower molecular weight band of AIF (tAIF) (Fig
4.1), suggesting lack of AIF processing despite NMDA/A23187 induced calpain
activation in the hippocampal cultures.
SH-SY5Y cells treated with low dose of thapsigargin (0.1 to 10 µM) for 24 h did
not demonstrate !-calpain autoproteolysis or AIF processing (Fig 4.4 A). High dose of
thapsigargin (100 µM) induced robust calpain activation as demonstrated by !-calpain
autoproteolysis (Fig 4.4 A), presence of 145 kD spectrin breakdown band (Fig 4.4 B) and
increased signal in the tBOC assay (Fig 4.4 C). It also demonstrated concomitant AIF
processing visualized as a faster migrating band on the immunoblot (Fig 4.4 A and D).

AIF distribution is insult dependent
To study the effect of calpain activation on AIF subcellular localization primary
hippocampal neurons were treated with NMDA or A23187 and SH-SY5Y cells were
treated with Thapsigargin. Following NMDA treatment there was significant change in
the cellular morphology and AIF distribution (Fig 4.2). AIF was observed to cluster
around the nucleus in a perinuclear notch along with mitochondria, but no AIF
immunostaining was detected in the nucleus (Fig 4.2), suggesting that under calpain
activation paradigms AIF is not necessarily translocated to the nucleus. The change in
cellular morphology and AIF distribution was sensitive to calpain inhibitor MDL28170
pretreatment (Fig 4.2). In contrast to NMDA, A23187 exposure induced robust nuclear
translocation of AIF, which was unaffected by MDL28170 pretreatment (Fig 4.3). In the
SH-SY5Y cells high dose (100 !M) thapsigargin induced AIF distribution to the cytosol
but did not demonstrate nuclear translocation of AIF (Fig 4.5).
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Table 4.1 Calpain activation, AIF processing, AIF distribution and effect of MDL on AIF
distribution in various treatment paradigms. Calpain activation is observed in NMDA and
A23187 treatment paradigms in the hippocampal neurons and in thapsigargin treatment
paradigm in the SH-SY5Y cells. AIF processing is observed in only high dose (100 !M)
thapsigargin treatment paradigm in the SH-SY5Y cells. AIF nuclear translocation is
observed in the A23187 treatment paradigm in the hippocampal neurons with or without
MDL28170 pretreatment. AIF cytosolic distribution is observed in the high dose (100 !M)
thapsigargin treatment paradigm in the SH-SY5Y cells. Abbreviations: NA- not
applicable, W.B. – Western blotting, I.C.C. – Immunocytochemistry.
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Table 4.1 Calpain activation, AIF processing, AIF distribution and effect of MDL28170 on
AIF distribution in various treatment paradigms.

Technique

Parameter

NMDA

A23187

Thapsigargin

W.B. - Spectrin

Calpain activation

+

+

+

W.B. - AIF

tAIF

-

-

+

I.C.C. - AIF

AIF extra

-

+

+

NA

-

NA

mitochondrial
distribution
I.C.C. - AIF

Effect of MDL on
AIF extra
mitochondrial
distribution
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Fig 4.1 NMDA or A23187 induced calpain activation does not lead to AIF processing.
Primary hippocampal neuronal cultures from E18 pups at 12 DIV were treated with
NMDA (100 !M) or calcium ionophore A23187 (10 !M) for the indicated time points.
Protein extracts were analyzed by SDS-PAGE and western blotting for spectrin and AIF.
Increased proteolysis of spectrin, demonstrating robust calpain activation in the cultures
following NMDA or A23187 exposure, was observed in both treatments at all time points.
Despite calpain activation no processing of AIF was visible on the immunoblot.
Representative western blots are shown. Antibodies used: Spectrin (Millipore cat. no.
MAB1622 ; 1:1000), AIF (E-1 clone ; Santa cruz biotechnology cat. no. sc-13116 ;
1:1000). Abbreviations: Cnt-Control, AIF-Apoptosis-inducing factor, E18-Embryonic day
18, DIV-Days in vitro.
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Fig 4.1 NMDA or A23187 induced calpain activation does not lead to AIF processing.
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Fig 4.2 AIF attains perinuclear staining following NMDA treatment. Primary hippocampal
neuronal cultures from E18 pups at 12 DIV were treated with NMDA (100 !M) overnight
in the presence or absence of MDL28170 (20 !M). Following incubation mitochondria
were stained by mitotracker red 580 nm (1 mM) (Red channel) for 15 min, then neurons
were fixed, permeabilized and immunostained for AIF (Green channel), and stained by
Hoechst for nucleus (Blue channel). Representative confocal photomicrographs of
neurons from three independent experiments are shown. Antibodies used: AIF (E-1
clone ; Santa cruz biotechnology cat. no. sc-13116 ; 1:50). Abbreviations: MDLMDL28170, AIF-Apoptosis-inducing factor, E-18-Embryonic day 18, DIV-Days in vitro.
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Fig 4.2 AIF attains perinuclear staining following NMDA treatment.
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Fig 4.3 AIF translocates to the nucleus following A23187 treatment. Primary
hippocampal neuronal cultures from E18 pups at 12 DIV were treated with calcium
ionophore A23187 (10 !M) for indicated time points in the presence or absence of
MDL28170 (20 !M). Following incubation mitochondria were stained by mitotracker red
580 nm (1 mM) (Red channel) for 15 min, then neurons were fixed, permeabilized and
immunostained for AIF (Green channel), and stained by Hoechst for nucleus (Blue
channel). Representative confocal photomicrographs of neurons from three independent
experiments are shown. Antibodies used: AIF (E-1 clone ; Santa cruz biotechnology cat.
no. sc-13116 ; 1:50). Abbreviations: MDL-MDL28170, AIF-Apoptosis-inducing factor, E18-Embryonic day 18, DIV-Days in vitro.
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Fig 4.3 AIF translocates to the nucleus following A23187 treatment.
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Hoechst
Blue Channel
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Fig 4.4 Thapsigargin-induced calpain activation is concomitant with AIF processing. SHSY5Y cells were exposed to ER stressor Thapsigargin (100 !M) for indicated time
points. Protein extracts were analyzed by SDS-PAGE and western blotting done for (A)
Calpain-1 and AIF, (B) Spectrin, and (D) AIF. No calpain activation or AIF proteolysis
was observed at low dose thapsigargin. Increased proteolysis of spectrin, demonstrating
robust calpain activation, and concomitant AIF processing was observed following high
dose (100 !M) of thapsigargin exposure at all time points. (C.) Representative images of
tBOC assay. tBOC (a substrate used for assaying calpain activation) was used to
analyze calpain activation. Images show robust calpain activation following high dose
(100 !M) thapsigargin exposure. Representative western blots and photomicrographs
are shown. The data are from at least three independent experiments, represented as
mean ±S.E.M, * indicates P<0.05 as per student’s unpaired t-test, relative to control.
Antibodies used: Calpain-1 (Abcam cat. no. ab28257 ; 1:2000), AIF (E-1 clone ; Santa
cruz biotechnology cat. no. sc-13116 ; 1:1000), Spectrin (Millipore cat. no. MAB1622 ;
1:1000). Abbreviations: Cnt-Control, AIF-Apoptosis-inducing factor, Th-Thapsigargin.
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Fig 4.4 Thapsigargin-induced calpain activation is concomitant with AIF processing.
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Fig 4.5 AIF shows cytosolic localization following high dose (100 µM) Thapsigargin
treatment. SH-SY5Y cells were exposed to the ER stressor Thapsigargin (100 !M) for
30 min. Following incubation mitochondria were stained by mitotracker red 580 nm (1
mM) (Red channel) for 15 min, and then cells were fixed, permeabilized and
immunostained for AIF (Green channel), and stained by Hoechst for nucleus (Blue
channel). Representative confocal photomicrographs of neurons from three independent
experiments are shown. Antibodies used: AIF (E-1 clone ; Santa cruz biotechnology cat.
no. sc-13116 ; 1:50). Abbreviations: ER-Endoplasmic reticulum.
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Fig 4.5 AIF shows cytosolic localization following high dose (100 µM) Thapsigargin
treatment.
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Discussion
The results of this study show that calpain activation does not necessarily lead to
AIF processing and nuclear translocation, but calpain may be one of the players for AIF
processing. Further we show that AIF can translocate to the nucleus in mature 62 kD
unprocessed form independent of calpain activity/proteolytic processing.
Spectrin is the main component of the cell membrane cytoskeleton (Czogalla and
Sikorski, 2005). It is a antiparallel heterodimer composed of 280 kD ! and 247-460 kD "
subunits, and exist as a tetramer in cytoskeleton (Czogalla and Sikorski, 2005). Spectrin
is a calpain substrate (Siman et al., 1984; Nixon, 1986) and is routinely used as a
marker for calpain activation (Wang, 2000). Excitotoxicity induces cell death by
excessive release of glutamate (Sattler and Tymianski, 2001) and majority of this occurs
by NMDA receptors (Wang et al., 2004). Primary hippocampal neuronal cultures
demonstrated calpain activation, by appearance of 150 kD and 145 kD bands of spectrin
breakdown, following NMDA exposure. AIF processing was not observed under these
conditions. This suggests that calpain activation does not necessarily lead to AIF
processing. Recently similar findings have been reported by Wang et al (Wang et al.,
2009b) where NMDA treatment lead to calpain activation but AIF was not processed.
NMDA exposure did not induce AIF translocation to the nucleus or cytosolic
distribution, instead AIF showed perinuclear notch localization along with mitochondria.
Mitochondria move towards nucleus under stress (Landshamer et al., 2008) and necrotic
signals (Laporte et al., 2007). Non translocation of AIF to the nucleus after NMDA
treatment contrasts with findings of Wang et al. 2004, but that may be due to the
difference in NMDA concentrations, length of treatment, and model system used. They
use 500 #M for 5 min, whereas we used 100 #M for longer periods of time. Also, they
used mice cortical cultures whereas our data is from rat hippocampal cultures. Overall,
the lack of AIF translocation to the nucleus following NMDA exposure is in agreement
with calpain’s inability to process AIF.
Hippocampal neurons treated with A23187, like NMDA treatment, showed
calpain activation, by appearance of 150 kD and 145 kD spectrin bands, and didn’t
demonstrate AIF processing. This suggests, like NMDA treatment, that calpain activation
does not necessarily lead to AIF processing. But in contrast to NMDA, A23187 treatment
demonstrated robust nuclear translocation of AIF. This suggests that AIF can translocate
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to the nucleus in full-length 62 kD form without getting processed to 57 kD tAIF. This
finding argues against the hypothesis that AIF has to be processed by a protease before
it gets released from the mitochondria (Otera et al., 2005). Recently, Wang et al reported
a similar finding regarding translocation of unprocessed 62 kD mature AIF to the nucleus
in an middle cerebral artery (MCA) occlusion model of ischemia and NMDA treated
primary neuronal cultures (Wang et al., 2009b). Possible mechanisms for mature 62 kD
AIF translocation to the nucleus could be compromised interaction of AIF’s hydrophobic
domain with the mitochondrial inner membrane, severe breaches in the integrity of the
mitochondrial inner membrane itself, changes in the redox state of the cell affecting
stability of AIF, presence of free floating mature 62 kD AIF in the mitochondrial IMS or
the presence of a second pool of AIF in the mitochondria in a different location (Wang et
al., 2009b). We also observed that A23187 induced AIF nuclear translocation occurred
in the presence of calpain inhibitor MDL28170, suggesting that AIF translocation can
occur independent of calpain activity. It is in agreement with a recent observation that
AIF translocates to the nucleus in calpain 4 knockout mice, which are functional calpain
knockouts, following N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) or NMDA treatment
(Wang et al., 2009b).
Besides mitochondria, endoplasmic reticulum (ER) is a major calcium buffering
organelle (Verkhratsky, 2005). Mitochondrial networks are closely intertwined with ER
tubules (Brookes et al., 2004; Pizzo and Pozzan, 2007) and VDAC physically interacts
with IP3 via grp75 (Szabadkai et al., 2006). There is apoptotic cross talk (Hacki et al.,
2000) and calcium cycling between mitochondria and ER (Mannella et al., 1998). The
intracellular region between ER and mitochondria is a calcium hotspot (Pizzo and
Pozzan, 2007)(Fig 1.3). Thus depletion of ER calcium store would locally increase
calcium concentration in the mitochondria-ER region, with a possibility of activating
mitochondrial !-calpain. ER stressor thapsigargin, induces Ca2+ dysregulation by
inhibiting the sarcoplasmic-endoplasmic reticulum Ca2+- ATPase pump (SERCA)
(Thastrup et al., 1990) in the SH-SY5Y cells (Nath et al., 1997) and induces cell death in
SH-SY5Y cells by involvement of ER and mitochondria (Kitamura et al., 2003).
In SH-SY5Y cells we did not observe !-calpain autoproteolysis at a low
concentration (0.1 to 10 µM) of thapsigargin for up to 24 h but robust calpain activation
was observed at higher concentration (100 µM) of thapsigargin demonstrated by !calpain autoproteolysis, spectrin breakdown products and tBOC assay. This indicates
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that !-calpain in the vicinity of mitochondria and ER is not easy to activate, suggesting
the possibility of a local inhibitory regulation. Our data contrasts with that of Harriman et
al (Harriman et al., 2002) where, in rabbit renal proximal tubules, low concentration (5
µM) of thapsigargin induced calcium deregulation and hydrolysis of a calpain substrate SLLVY-AMC within 2 min, demonstrating calpain activation. This could be explained by
the fact that calpain substrate assays are not specific for !-calpain.
In SH-SY5Y cells we did not observe AIF processing at low concentration (0.1 to
10 µM) of thapsigargin for up to 24 h. In NIH3T3 cells AIF, along with caspase-12, is
processed following treatment with low concentration (2 µM) of thapsigargin for 48 h in a
calpain dependent fashion with no involvement of executioner caspases (Sanges and
Marigo, 2006). There was extensive cell death observed in SH-SY5Y cells following
treatment for 48 h. It is also noteworthy that SH-SY5Y cells treated at lower dose (nM to
5 !M) of thapsigargin for extended period of times have demonstrated caspase 2, 3, and
7 activation and protection by pretreatment with Z-VAD-FMK but not by calpain inhibitor
III (Arai et al., 2004; Dahmer, 2005; Muruganandan and Cribb, 2006). This suggests that
in neuroblastoma cells low dose thapsigargin induces a caspase-dependent apoptotic
cascade. We observed AIF processing only at a very high concentration (100 !M) of
thapsigargin treatment, concomitant with robust and specific calpain activation
demonstrated by autoproteolysis and 145 kD spectrin breakdown band. Pretreatment
with MDL28170 (20 µM) had no effect on AIF processing at high concentration (100 µM)
of thapsigargin treatment. One concern with the high concentration of thapsigargin is
that thapsigargin could become non-specific and activate other cell death pathways
besides calcium dysregulation such as unfolding protein response and/or ER-directed
protein degradation by proteosome.
AIF translocates to the nucleus, along with caspase-12, following low dose (2
µM) of thapsigargin treatment for 48 h in NIH3T3 cells in a calpain dependent fashion
(Sanges and Marigo, 2006) but we were unable to demonstrate AIF nuclear
translocation with low dose thapsigargin in the SH-SY5Y cells (results not shown). At the
high concentration (100 µM) of thapsigargin we did not detect AIF nuclear translocation
rather detected only cytosolic distribution of AIF. Pretreatment with MDL28170 (20 µM)
had no effect on the AIF redistribution following high concentration (100 µM) of
thapsigargin treatment. As the length and strength of an insult determines which cell
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death cascades are activated (Meli et al., 2004), AIF processing and distribution may
also depend upon the cell type and insult strength and duration.
BCL-2 family of proteins regulates AIF translocation (Cregan et al., 2002).
Apoptosis-inducing factor (AIF) proteolytic processing and mitochondrial release were
both inhibited by overexpression of BCL-2 and BCL-XL (Daugas et al., 2000b; Otera et
al., 2005). Bid inhibitor and Bid siRNA prevented the AIF release and translocation in
HT-22 neurons (Landshamer et al., 2008). These literature evidence suggests that outer
mitochondrial membrane permeabilization is upstream of AIF processing and nuclear
translocation, indicating necessity for import of something from cytosol for AIF
processing and subsequent nuclear translocation. Possibility of calpain (cytosolic µcalpain) getting translocated to the mitochondria and playing a role in AIF processing
and nuclear translocation has been addressed in this chapter to a certain extent. Our
results demonstrate that calpain activation does not necessarily lead to AIF processing,
AIF can translocate to the nucleus independent of calpain activation and as a full length
mature 62 kD AIF without any processing. These results also show that calpain
activation and AIF processing are concomitant under stringent ER stress signals. This
suggests a possibility of calpain mediated AIF processing but whether calpain is directly
involved in AIF processing or is indirectly processing AIF via lysosomal cathepsins
needs further investigation. Since mitochondrial outer membrane permeabilization is
upstream of AIF processing and nuclear translocation, other possibilities such as
mitochondrial translocation of an activator of endogenous AIF cleaving mitochondrial
protease, mitochondrial release of the AIF cleaving protease’s inhibitor (Modjtahedi et
al., 2006) or import of additional pro-apoptotic cytosolic factors to the mitochondria that
could facilitate AIF processing and nuclear translocation also needs further investigation.
Finally, there could be multiple mechanisms for the processing and distribution (nuclear
or cytosolic) of AIF in the cells, certainly at least one without involvement of calpains.

Copyright © Aashish Joshi 2009
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Chapter Five
Calpastatin localization in the mitochondrial intermembrane space
Aashish Joshi, Vimala Bondada, Dingyuan Lou, and James W. Geddes
“The most exciting phrase to hear in science, the one that heralds new discoveries, is
not 'Eureka!' but 'That's funny...”- Isaac Asimov

Introduction
The calpain proteolytic system is comprised of the calpain family of cysteine
proteases, their specific endogenous inhibitor calpastatin (Dayton et al., 1976; Croall and
DeMartino, 1991; Mellgren, 1991; Brustis et al., 1994; De Jongh et al., 1994; Shea et al.,
1995) and activator calcium (Goll et al., 2003). Calpastatin inhibits calpains in a
reversible calcium dependent manner (Cottin et al., 1981; Imajoh and Suzuki, 1985;
Otsuka and Goll, 1987; Wendt et al., 2004; Hanna et al., 2007; Hanna et al., 2008).
Calpastatin, being an indispensible component of the calpain proteolytic system, plays a
key regulatory role in various physiological functions such as cell cycle progression
(Zhang et al., 1997), proliferation (Zhang et al., 1996), differentiation (Grynspan et al.,
1997a; Patel and Lane, 2000), migration (Franco et al., 2004; Satish et al., 2005; Wu et
al., 2006), synaptic remodeling and long term potentiation (Tomimatsu et al., 2002),
embryonic development (Arthur et al., 2000), meiosis and mitosis (Schollmeyer, 1988;
Santella et al., 2000) as well as pathological states including muscular dystrophy
(Richard et al., 1995), diabetes (Horikawa et al., 2000), Alzheimer’s disease (Grynspan
et al., 1997b; Tsuji et al., 1998), cataract (Nakamura et al., 2000), multiple sclerosis
(Shields et al., 1999), neuronal ischemia (Saido et al., 1993b; Roberts-Lewis et al.,
1994), obsessive compulsive disorder (Mundo et al., 1997) and traumatic brain and
spinal cord injuries (Springer et al., 1997; Pike et al., 2001; Goll et al., 2003; Liu et al.,
2004).
The single calpastatin molecule has four inhibitory repeats, capable of inhibiting
one calpain molecule each (Maki et al., 1987; Goll et al., 2003) and an N-terminal L
domain which lacks inhibitory activity (Averna et al., 2001). An additional N-terminal XL
domain has been identified in bovine calpastatin (Cong et al., 1998). There are various
isoforms of calpastatin with different domain combinations due to alternative splicing
(Lee et al., 1992a; Lee et al., 1992b; Takano et al., 2000), exon skipping (De Tullio et al.,
2007), and usage of different promoters (Imajoh et al., 1987; Cong et al., 1998). Multiple
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isoforms are found in a single tissue (Melloni et al., 1998b). Molecular weight range of
the various calpastatin isoforms is 17.5 kD to 85 kD (Goll et al., 2003) and they migrate
aberrantly on SDS-PAGE (Takano and Murachi, 1982a; Maki et al., 1991). The
functional significance of so many different isoforms is not known. Calpastatin’s
inhibitory activity is regulated by protein’s abundance and by post translational
modifications (Cong et al., 1998) including phosphorylation (Salamino et al., 1994;
Salamino et al., 1997). There might be additional components to the regulation of
calpastatin activity, one possible mechanism being the differential subcellular
compartmentalization of different isoforms of calpastatin.
Calpastatin was thought to be primarily a cytosolic protein (Taylor et al., 1991;
Kumamoto et al., 1995). In SH-SY5Y cells 90% of calpastatin is cytosolic (Grynspan et
al., 1997a). Recently along with calpain, calpastatin was found to be associated with ER
and golgi fractions (Hood et al., 2003; Hood et al., 2004). It is reported that calpastatin is
associated with the inner mitochondrial membrane of the pulmonary smooth muscle
mitochondria (Kar et al., 2007; Kar et al., 2008) however other studies did not find
calpastatin in the mitochondria (Ozaki et al., 2007). We recently localized !-calpain to
the mitochondrial intermembrane space (Badugu et al., 2008) and hypothesized that this
location would protect µ-calpain from calpastatin, thus making its activation easier. We
observed that mitochondrial !-calpain requires high calcium levels (in mM) for activation
(Joshi et al., 2009). The reason behind this high calcium requirement was not
determined, with one possibility being the presence of a calpain inhibitor, calpastatin, in
the neuronal mitochondria.
The goal of this study was to evaluate the hypothesis that calpastatin is present
in the neuronal mitochondria. In the present study we have identified calpastatin in the
mitochondrial intermembrane space of the mitochondria isolated from the rat cerebral
cortex and SH-SY5Y cells. Further our results demonstrate that the N-terminal first 30
amino acids of calpastatin’s XL domain are a mitochondrial targeting sequence.
Identification of calpastatin in the mitochondrial intermembrane space and unraveling its
possible mechanism of import into mitochondria provides a novel mechanism for
regulating the activity of mitochondrial !-calpain in the mitochondrial intermembrane
space.
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Results
Calpastatin is associated with the mitochondria
Purified !-calpain is activated at micromolar calcium concentrations (Suzuki,
1991). We observed that mitochondrial !-calpain requires high calcium levels (5 mM) for
activation (Fig 5.1) (Joshi et al., 2009). Thus, we probed for the calpain inhibitor calpastatin, in mitochondria-enriched fraction of the SH-SY5Y cells and rat cerebral
cortex. Calpastatin immunoreactivity was stronger in the mitochondria-enriched fraction
from both SH-SY5Y cells (Fig 5.2) and rat cerebral cortex (Fig 5.6), relative to the
corresponding homogenate samples.

Calpastatin is located in the mitochondrial intermembrane space
To determine whether calpastatin is inside the mitochondria or is associated on
the outer face of the outer mitochondrial membrane, mitochondria-enriched fractions of
the SH-SY5Y cells and rat cerebral cortex were incubated with enzyme proteinase K.
The calpastatin results were compared to AIF, which is located inside the mitochondrial
outer membrane. Calpastatin and AIF immunoreactivity persisted following proteinase K
incubation in the SH-SY5Y mitochondria (Fig 5.3). Calpastatin immunoreactivity
persisted following proteinase K incubation in the rat cerebral cortex mitochondria (Fig
5.7). This suggests that calpastatin is localized inside the outer mitochondrial
membrane. To confirm the activity of proteinase K, mitochondrial fractions were
solubilized with 0.2% Triton-X 100 and then incubated with proteinase K. Both
calpastatin and AIF immunoreactivity were lost (Fig 5.3 and Fig 5.7) demonstrating that
proteinase K was active.
To determine the submitochondrial localization of calpastatin, Percoll-enriched
mitochondria of the SH-SY5Y cells and rat cerebral cortex were subfractionated via
hypotonic rupture into their components namely Mitoplasts (inner mitochondrial
membrane and matrix), Intermembrane space, and Outer mitochondrial membrane.
Calpastatin immunoreactivity was found in the mitoplast and intermembrane space
fractions but not in the outer mitochondrial membrane fraction in both SH-SY5Y cells
(Fig 5.4) and rat cerebral cortex (Fig 5.8). AIF immunoreactivity, consistent with its
localization, was observed in the mitoplast fraction but not in the outer mitochondrial
membrane fraction or intermembrane space fraction (Fig 5.4 and Fig 5.8).
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To determine whether calpastatin is inside the mitoplast (i.e. matrix) or is
associated with the outer face of the inner mitochondrial membrane, SH-SY5Y cells
mitoplasts were incubated with proteinase K. Calpastatin immunoreactivity was lost
following proteinase K incubation, suggesting that calpastatin is associated with the
outer face of the inner mitochondrial membrane (Fig 5.5 A). AIF was also digested in
mitoplasts with proteinase K, observed as faster migrating band (Fig 5.5 B), though the
digestion was not complete as AIF is a trans inner membrane protein. Matrix protein
mHSP70, as expected, was protected from proteinase K digestion (Fig 5.5 C). To
confirm the activity of proteinase K, mitoplast fractions were solubilized with 0.2% TritonX 100 and then incubated with proteinase K. Calpastatin, AIF and mHSP70
immunoreactivities were lost following solubilization indicating that proteinase K was
active (Fig 5.5 A, B and C).

Mitochondrial targeting sequence in calpastatin
The majority of mitochondrial proteins, including all IMS proteins, are nuclear
encoded, synthesized in the cytosol, and subsequently imported from the cytosol into the
mitochondria (Anderson et al., 1981; Poyton and McEwen, 1996; Scarpulla, 2002).
There are various mechanisms of mitochondrial protein import. Large IMS proteins are
imported by interaction with TOM and TIM, via an N-terminal mitochondrial targeting
sequence (Herrmann and Hell, 2005). In silico sequence analysis of the calpastatin
protein using four different programs– iPSORT (Bannai et al., 2002), SLPFA (Tamura
and Akutsu, 2007), Target P 1.1 server (Emanuelsson et al., 2007), and MitoProt IIv1.101 (Claros and Vincens, 1996) predicted mitochondrial localization of calpastatin
(Fig 5.9 A), with first 30 amino acids of the XL-domain of calpastatin being the
mitochondrial targeting sequence (Fig 5.9 B). There was 73.3% sequence identity
between first 30 amino acids of rat and human calpastatin sequence, suggesting
possibly the same mechanism of calpastatin import to mitochondria in these two species
(Fig 5.9 C). Based on the subcellular location prediction programs we incorporated first
30 amino acids of the XL domain of rat calpastatin (1-30XLDCAST) into a mammalian
GFP expression vector - pWPXL. 1-30XLDCAST-pWPXL vector when transfected to
SH-SY5Y cells had a tubular distribution which co-localized with mitochondrial dye
mitotracker red (Fig 5.10), suggesting that the first 30 amino acids of the XL domain of
calpastatin are a mitochondrial targeting sequence.
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Fig 5.1 Mitochondrial !-calpain requires high calcium concentration for activation.
Percoll-enriched SH-SY5Y cells mitochondria were incubated with two different
concentrations of calcium in Tris-HCl based calpain activity buffer for 2 h at room
temperature. Samples were probed for !-calpain activation by western blotting using
either calpain-1 domain III antibody or N-terminal calpain-1 antibody. Calpain activation
results in autoproteolysis of calpain at N-terminus. Thus, calpain activation is visualized
either as a faster migrating band with domain III antibody or as a loss of
immunoreactivity with N-terminal antibody. Mitochondrial !-calpain was not activated
with 0.5 mM Ca2+ incubation, but was activated following 5 mM Ca2+ incubation.
Representative western blots are shown. Antibodies used: µ-calpain domain III
(Calbiochem cat. no. 208728 ; 1:2000), µ-calpain N-terminal (Abcam cat. no. ab28257 ;
1:2000). Abbreviations: Cnt-Control.
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Fig 5.1 Mitochondrial !-calpain requires high calcium concentration for activation.
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Fig 5.2 Calpastatin is associated with the mitochondrial fraction from the SH-SY5Y cells.
The starting homogenate and the Percoll-enriched mitochondria from SH-SY5Y cells
were analyzed for the presence of calpastatin by SDS-PAGE and western blotting.
Mitochondrial fraction showed enrichment of calpastatin immunoreactivity relative to
homogenate. Equal amounts of protein were loaded in each lane as determined by BCA
protein assay. Representative western blot is shown. Antibodies used: Calpastatin
(Chemicon cat. no. MAB3084 ; 1:1000). Abbreviations: CAST-Calpastatin, HHomogenate, M-Mitochondrial fraction.
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Fig 5.2 Calpastatin is associated with the mitochondrial fraction from the SH-SY5Y cells.
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Fig 5.3 Calpastatin is located inside the mitochondria from the SH-SY5Y cells. Percollenriched mitochondria from the SH-SY5Y cells were incubated with proteinase K (50
!g/ml) for 30 min at 37 °C, with or without 0.2% Triton-X 100 solubilization. PMSF (2
mM) was added to the reaction to terminate proteinase K activity. Samples were
resolved by SDS-PAGE and analyzed by western blotting for calpastatin and AIF. (A.)
Calpastatin immunoreactivity persisted in non-solubilized proteinase K treated
mitochondria, but was lost in 0.2% Triton-X 100 solubilized proteinase K treated
mitochondria. (B.) AIF, an intramitochondrial protein, was protected from proteinase K
digestion in non-solubilized mitochondria. This suggests calpastatin is present inside the
outer mitochondrial membrane. Representative western blots are shown. Antibodies
used: Calpastatin (Chemicon cat. no. MAB3084 ; 1:1000), AIF (E-1 clone ; Santa cruz
biotechnology cat. no. sc-13116 ; 1:1000). Abbreviations: CAST-Calpastatin, AIFApoptosis-inducing factor, PK-Proteinase K, Tx-0.2% Triton-X 100, Cnt-Control.
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Fig 5.3 Calpastatin is located inside the mitochondria from the SH-SY5Y cells.
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Fig 5.4 Calpastatin is present in the mitochondrial intermembrane space and mitoplast
fractions from the SH-SY5Y cells. The outer mitochondrial membrane of Percollenriched mitochondria from SH-SY5Y cells was disrupted by incubation in a hypotonic
(10 mM HEPES/KOH, pH 7.4) solution at 4 °C for 20 min. Mitoplasts (MP) were pelleted
by centrifugation at 1900 g for 15 min at 4 °C. The supernatant fraction was further
centrifuged at 35,000 g for 15 min at 4 °C to pellet the outer mitochondrial membrane
fragments (OMM) and supernatant fraction was the intermembrane space (IMS).
Samples were resolved by SDS-PAGE and analyzed by western blotting for calpastatin
and AIF. (A.) Calpastatin immunoreactivity was detected in the mitochondria, mitoplast
and intermembrane space fraction but not in the mitochondrial outer membrane fraction.
(B.) AIF immunoreactivity was detected in the mitochondria and mitoplast fraction.
Representative western blots are shown. Antibodies used: Calpastatin (Chemicon cat.
no. MAB3084 ; 1:1000), AIF (E-1 clone ; Santa cruz biotechnology cat. no. sc-13116 ;
1:1000). Abbreviations: CAST-Calpastatin, AIF-Apoptosis-inducing factor, MMitochondrial fraction, MP-Mitoplast, IMS-Intermembrane Space, OMM-Outer
mitochondrial membrane fraction.
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Fig 5.4 Calpastatin is present in the mitochondrial intermembrane space and mitoplast
fractions from the SH-SY5Y cells.
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Fig 5.5 Calpastatin is located on the inner mitochondrial membrane in the SH-SY5Y cells
mitochondria. The outer mitochondrial membrane of Percoll-enriched mitochondria from
SH-SY5Y cells was disrupted by incubation in a hypotonic (10 mM HEPES/KOH, pH 7.4)
solution at 4 °C for 20 min. Mitoplasts (MP) were pelleted by centrifugation at 1900 g for
15 min at 4 °C. Mitoplasts were then incubated with proteinase K (50 !g/ml) for 30 min
at 37 °C, with or without 0.2% Triton-X 100 solubilization. PMSF (2 mM) was added to
the reaction to terminate proteinase K activity. Samples were resolved by SDS-PAGE
and analyzed by western blotting for calpastatin, mHSP70 and AIF. (A.) Calpastatin
immunoreactivity was lost following proteinase K incubation in both non-solubilized
mitoplasts and 0.2% Triton-X 100 solubilized mitoplasts. (B.) mHSP70, a matrix protein,
was protected from proteinase K digestion in non-solubilized mitoplasts. (C.) AIF, an
inner membrane protein, was processed with proteinase K digestion in non-solubilized
mitoplasts. This suggests calpastatin is primarily present in the mitochondrial
intermembrane space and on the outer face of the inner mitochondrial membrane.
Representative western blots are shown. Antibodies used: Calpastatin (Chemicon cat.
no. MAB3084 ; 1:1000), mHSP70 (Affinity Bioreagents cat. no. MA3-028 ; 1:10000), AIF
(E-1 clone ; Santa cruz biotechnology cat. no. sc-13116 ; 1:1000). Abbreviations: CASTCalpastatin, AIF-Apoptosis-inducing factor, mHSP70-Mitochondrial heat shock protein
70, PK-Proteinase K, Tx-Triton-X 100 and Cnt-Control.
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Fig 5.5 Calpastatin is located on the inner mitochondrial membrane in the SH-SY5Y cells
mitochondria.
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Fig 5.6 Calpastatin is associated with the mitochondrial fraction from the rat cerebral
cortex. The starting homogenate, after differential fraction and the Percoll-enriched
mitochondrial fraction from rat cerebral cortex were analyzed for the presence of
calpastatin by SDS-PAGE and western blotting. Mitochondrial fraction showed
enrichment of calpastatin immunoreactivity relative to homogenate and after differential
fractions. Equal amount of protein was loaded in each lane as determined by BCA
protein assay. Representative western blot is shown. Antibodies used: Calpastatin
(Chemicon cat. no. MAB3084 ; 1:1000). Abbreviations: CAST-Calpastatin, HHomogenate, D-After differential fraction, M-Mitochondrial fraction.
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Fig 5.6 Calpastatin is associated with the mitochondrial fraction from the rat cerebral
cortex.
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Fig 5.7 Calpastatin is located inside the mitochondria from the rat cerebral cortex.
Percoll-enriched mitochondria from rat cerebral cortex were incubated with proteinase K
(50 !g/ml) for 30 min at 37 °C, with or without 0.2% Triton-X 100 solubilization. PMSF (2
mM) was added to the reaction to terminate proteinase K activity. Samples were
resolved by SDS-PAGE and analyzed by western blotting for calpastatin. Calpastatin
immunoreactivity persisted in non-solubilized proteinase K treated mitochondria, but was
lost in 0.2% Triton-X 100 solubilized proteinase K treated mitochondria. This suggests
calpastatin is present inside the outer mitochondrial membrane. Representative western
blot is shown. Antibodies used: Calpastatin (Chemicon cat. no. MAB3084 ; 1:1000).
Abbreviations: CAST-Calpastatin, PK-Proteinase K, Tx-0.2% Triton-X 100, Cnt-Control.
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Fig 5.7 Calpastatin is located inside the mitochondria from the rat cerebral cortex.
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Fig 5.8 Calpastatin is present in the mitochondrial intermembrane space and mitoplast
fractions from the rat cerebral cortex. The outer mitochondrial membrane of Percollenriched mitochondria from rat cerebral cortex was disrupted by incubation in a
hypotonic (10 mM HEPES/KOH, pH 7.4) solution at 4 °C for 20 min. Mitoplasts (MP)
were pelleted by centrifugation at 1900 g for 15 min at 4 °C. The supernatant fraction
was further centrifuged at 35,000 g for 15 min at 4 °C to pellet the outer mitochondrial
membrane fragments (OMM) and supernatant fraction was the intermembrane space
(IMS). Samples were resolved by SDS-PAGE and analyzed by western blotting for
calpastatin and AIF. (A.) Calpastatin immunoreactivity was detected in the mitochondria,
mitoplast and intermembrane space fraction but not in the mitochondrial outer
membrane fraction. (B.) AIF immunoreactivity was detected in the mitochondria and
mitoplast fraction. Representative western blots are shown. Antibodies used: Calpastatin
(Chemicon cat. no. MAB3084 ; 1:1000), AIF (E-1 clone ; Santa cruz biotechnology cat.
no. sc-13116 ; 1:1000). Abbreviations: CAST-Calpastatin, AIF-Apoptosis-inducing factor,
M-Mitochondrial fraction, MP-Mitoplast, IMS-Intermembrane Space, OMM-Outer
mitochondrial membrane fraction.
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Fig 5.8 Calpastatin is present in the mitochondrial intermembrane space and mitoplast
fractions from the rat cerebral cortex.
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Fig 5.9 N-terminal 1-30 amino acids of the XL domain of calpastatin are predicted to be
a mitochondrial targeting sequence. (A.) In silico sequence analysis of calpastatin by
four different softwares. All of them predict mitochondrial localization of calpastatin. (B.)
First 30 amino acids of the XL domain of calpastatin are predicted as a mitochondrial
targeting sequence. (C.) There is 73.3% identity in the first 30 amino acids of rat and
human calpastatin sequence.
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Fig 5.9 N-terminal 1-30 amino acids of the XL domain of calpastatin are predicted to be
a mitochondrial targeting sequence.
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Fig 5.10 1-30XLDCAST-pWPXL shows mitochondrial localization. N-terminal first 30
amino acids of the XL domain of rat calpastatin were PCR amplified and ligated into a
mammalian GFP expression vector. Transfection of this GFP tagged first 30 amino acids
of the XL domain of calpastatin (1-30XLDCAST-pWPXL) into SH-SY5Y cells showed
tubular localization that co-localized with the mitochondrial stain mitotracker red.
Representative confocal images are shown. Abbreviations: PCR-Polymerase chain
reaction, GFP-Green fluorescent protein, pWPXL-Plasmid WPXL, 1-30XLDCAST-First
30 amino acids XL domain calpastatin.
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Fig 5.10 1-30XLDCAST-pWPXL shows mitochondrial localization.
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Discussion
The purpose of this study was to examine the hypothesis that the calpain
inhibitor, calpastatin, is present in the CNS mitochondria. Results of this study
demonstrate that calpastatin is associated with the Percoll-enriched mitochondria from
SH-SY5Y neuroblastoma cells and rat cerebral cortex. Further we show that calpastatin
is located in the mitochondrial intermembrane space by mitochondrial subfractionation
and proteinase K protection assay. The results also demonstrate that the first 30 amino
acids of calpastatin’s XL domain act as a mitochondrial targeting sequence.
Calpastatin immunoreactivity was significantly enriched in the Percoll-enriched
mitochondrial fraction of SH-SY5Y cells and rat cerebral cortex, relative to corresponding
homogenates, demonstrating the presence of calpastatin in the mitochondria. Previously
calpastatin was predominantly localized to the cytosol (Takano and Murachi, 1982b;
Adachi et al., 1991; Taylor et al., 1991; Kumamoto et al., 1997; Tullio et al., 1999; Ozaki
et al., 2007). Recently calpastatin has been reported to be present in various subcellular
compartments along with calpain (Barnoy et al., 1999; Hood et al., 2003; Hood et al.,
2004; Haim et al., 2006). Calpastatin immunoreactivity was protected by proteinase K
digestion of mitochondria implying its location to be internal to the mitochondrial outer
membrane. We further explored the submitochondrial localization of calpastatin by
submitochondrial fractionation using HEPES based hypo-osmotic shock. Calpastatin
was found in the mitochondrial intermembrane space and mitoplasts but not in the outer
mitochondrial membrane. Mitoplast associated calpastatin was digested by proteinase K
suggesting it is localized on the outer face of the mitochondrial inner membrane.
Calpastatin has been demonstrated to be located on the pulmonary smooth muscle
mitochondrial inner membrane facing intermembrane space (Kar et al., 2008). This is in
agreement with our finding of calpastatin in the mitochondrial intermembrane space and
inner mitochondrial membrane fractions from SH-SY5Y cells and rat cerebral cortex.
The presence of calpastatin in the mitochondrial intermembrane space, the same
submitochondrial compartment as mitochondrial !-calpain, helps to explain various
observations. The lack of involvement of mitochondrial !-calpain in AIF processing
following mPTP (Joshi et al., 2009) could be due to the presence of calpastatin in the
same mitochondrial compartment as !-calpain. Release of AIF from the isolated brain
mitochondria required addition of exogenous calpain (Polster et al., 2005), which could
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also be due to the presence of calpastatin within mitochondria. This also explains why
mitochondrial !-calpain requires high calcium (mM) for activation.
Rat brain has multiple mRNA’s for calpastatin (De Tullio et al., 1998) encoding
different isoforms of calpastatin. Calpastatin is present in rat brain as at least six
alternatively spliced isoforms having combinations of XL, L, and four inhibitory repeats
(De Tullio et al., 1998). Such heterogeneity in a single protein suggests likelihood of
functional significance of the different isoforms, which is as yet unknown. One possibility
is that the different isoforms are modified differentially by post-translational modifications
to cater to various cellular needs. An alternate possibility is that different domain
combinations target calpastatin to different subcellular locations.
XL domain containing calpastatin, similar to type I calpastatin, has been recently
identified in the rat brain (De Tullio et al., 2007). XL domain containing calpastatin has
various combinations of exons 4, 6, and 8. XL domain of calpastatin does not affect
calpain calpastatin complex formation in the absence of calcium (De Tullio et al., 2007).
Thus the function of XL domain of CAST has yet not been identified. Calpastatin is not
encoded in the mitochondria, like most mitochondrial proteins it has to be imported from
the cytosol. The mechanism of calpastatin import to the mitochondria is also unresolved
so far. A chimeric protein consisting of the N-terminus 30 amino acids of XL domain of
calpastatin and GFP showed mitochondrial localization, suggesting that first 30 amino
acids of XL domain of calpastatin are a mitochondrial targeting sequence. This ascribes
function to the XL domain of calpastatin. Whether calpastatin is exclusively in the
intermembrane space or it is an inner mitochondrial membrane anchored protein
remains purely speculative at this point. Class I intermembrane space proteins have a
bipartite sequence (Herrmann and Hell, 2005). They are imported via a leading Nterminus mitochondrial targeting sequence, which may be processed by a protease in
the matrix, and second hydrophobic sorting domain which locks protein in the inner
mitochondrial membrane (Herrmann and Hell, 2005). Though calpastatin has a leading
N-terminus mitochondrial targeting sequence and a predicted cleavage site at the 18th
amino acid position it lacks an amphipathic helix in the N-terminus and a hydrophobic
sorting domain on the hydropathicity plot. Further we noticed that AIF, which is an inner
mitochondrial membrane anchored protein, is not found in the IMS fraction on
mitochondrial subfractionation of SH-SY5Y cellular or rat cerebral cortex mitochondria
but calpastatin, unlike AIF, is detected in the IMS fraction. Calpastatin has a stretch of
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positively charged amino acids lys-lys-arg-his-lys-lys in the L – domain. Thus it is highly
likely that calpastatin electrostatically binds to the mitochondrial inner membrane (Hood
et al., 2004) and is not a membrane anchored protein.
The efficiency and level of calpastatin are crucial in regulating calpain activity
(Pontremoli et al., 1988), but the isoform variability may be an additional regulatory
component by preferentially targeting XL domain containing calpastatin to the
mitochondrial intermembrane space. It is highly likely that other isoforms thus may be
targeted to other subcellular locations, which needs further investigation. Transcriptional
modulation of calpastatin isoforms may thus modulate the amount of calpastatin in
various subcellular compartments including mitochondria. Hence this could be a novel
mechanism that ultimately effects localized calpain activation and the outcome
thereafter, producing varied pathology and physiological response of a cell to similar
levels of increased calcium.
The immunoreactivity of mitochondrial calpastatin in the SH-SY5Y cells was
detected at 110 kD. Cong et al (Cong et al., 1998) showed that the XL domain
containing calpastatin runs at 145 kD. One possible explanation could be a processing
event after mitochondrial import. Mitochondrial proteins imported by mechanism of Nterminal mitochondrial targeting sequence are processed by a matrix protease after the
import (Herrmann and Hell, 2005). Thus XL domain calpastatin might undergo similar
cleavage following import and thus runs at a lower molecular weight. Rat cerebral cortex
mitochondrial calpastatin was detected at 70 kD. Mitochondrial !-calpain may get
activated during or prior to the isolation procedure (Garcia et al., 2005). Calpastatin is a
calpain substrate (DeMartino et al., 1988; Carragher et al., 2002; Goll et al., 2003) and
calpastatin can be degraded due to ischemia by calpain into a 50 kD protein (Blomgren
et al., 1999). It is possible that mitochondrial calpastatin gets proteolysed by
mitochondrial !-calpain during isolation.
In summary identification of calpastatin in the mitochondrial intermembrane
space, the same submitochondrial compartment as mitochondrial !-calpain provides
useful insight into questions related to the activation, substrates and function of
mitochondrial !-calpain. The results also suggest a possible mechanism of import of
calpastatin to the mitochondrial intermembrane space and ascribe novel function to the
XL domain of calpastatin.
Copyright © Aashish Joshi 2009
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Chapter six
Summary and Conclusions
“The essential matter of history is not what happened but what people thought or said
about it.”- Frederic William Maitland
Calcium deregulation is central to the secondary neurodegeneration in traumatic
neuronal injuries (Happel et al., 1981; Choi, 1988; Chesler et al., 1994; Saatman et al.,
1996b). Mitochondria are one of the prime organelles to be involved in calcium
regulation and deregulation (Rego and Oliveira, 2003; Bernardi and Rasola, 2007).
Calpains, being calcium dependent proteases, are one of the key players in neuronal
death resulting from calcium deregulation (Goll et al., 2003). Predominant ubiquitous
isoforms of calpains present in the CNS are µ and m-calpain (Croall and DeMartino,
1991). m-Calpain caters to the physiological needs of the cell (Franco et al., 2004; Dutt
et al., 2006) and is extra mitochondrial whereas µ-calpain has evidence for being tagged
as a pathologic isoform (Siman et al., 1985; Roberts-Lewis et al., 1994; Azam et al.,
2001; Cao et al., 2007) and is located in the mitochondrial intermembrane space
(Badugu et al., 2008) as well as the cytosol. Thus, developing a better understanding of
the mitochondrial µ-calpain could address the pathological consequences of calpain
hyper-activation while simultaneously sparing normal cellular functions. The primary
objective of this dissertation was to gain insightful understanding into
mitochondrial µ-calpain’s function, with a focus on its putative role in the
processing of apoptosis-inducing factor, and mitochondrial µ-calpain’s regulation.
Calpains are involved in wide variety of functions, both physiological and
pathological (Goll et al., 2003). There are numerous known calpain substrates including
cytoskeletal proteins, cell signaling proteins, and calcium regulatory proteins (Bevers
and Neumar, 2008). In previous studies of TBI, calpain inhibition demonstrated
functional improvement (Saatman et al., 1996b) but without decrease in the cytoskeletal
proteolysis, lesion volume or apoptosis (Saatman et al., 2000; Kupina et al., 2001),
suggestive of some novel protein as a crucial substrate for calpain mediated
neurodegeneration. There are number of mitochondrial proteins which are known to be
calpain substrates such as AIF, BAX, BCL-XL, Bid, and NCX (Nakagawa and Yuan,
2000; Chen et al., 2001; Choi et al., 2001; Polster et al., 2005; Takano et al., 2005; Kar
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et al., 2009). It is highly likely that these proteins could be processed by endogenous
mitochondrial µ-calpain, whose function and substrates have not been addressed.
Apoptosis-inducing factor (AIF) had very high probability of being a mitochondrial µcalpain substrate because of its localization in the mitochondrial intermembrane spacethe same intra-organelle compartment as mitochondrial µ-calpain (Garcia et al., 2005;
Badugu et al., 2008), its requirement for processing at the N-terminus by an unknown
protease to get detached from the inner mitochondrial membrane association (Otera et
al., 2005), its essential role in inducing CICD (Cregan et al., 2002; Boujrad et al., 2007)
which is documented to be involved in variety of neurodegenerative diseases (Cao et al.,
2003; Plesnila et al., 2004; Liou et al., 2005; Yu et al., 2006a; Yu et al., 2006b; Wales et
al., 2008) and evidence that AIF is cleaved by exogenous µ-calpain in isolated
mitochondria (Polster et al., 2005) or in the cell culture models (Artus et al., 2006; Cao et
al., 2007; Norberg et al., 2008; Wales et al., 2008; Mader et al., 2009). Identification of a
protease which processes AIF and leads to CICD would help in inhibiting AIF release
and translocation to the nucleus and also prevent the compromise in mitochondrial
function due to AIF release. AIF being processed by endogenous mitochondrial µcalpain seemed a very logical hypothesis. We thus studied the role of endogenous
mitochondrial µ-calpain in AIF processing.
Chapter 3 of this dissertation provides evidence that mitochondrial µ-calpain is
not involved in the processing of apoptosis-inducing factor. Atractyloside, an mPTP
inducer, induced release of truncated AIF from the Percoll-enriched rat liver mitochondria
following permeability transition pore formation. The release of Atr-induced tAIF occurred
even in the presence of calpain inhibitors and mitochondrial µ-calpain immunoreactivity
was difficult to detect in these mitochondria. This suggests that mitochondrial µ-calpain
is not required for AIF processing and release. Inhibition of AIF release and processing
following Atr incubation by MDL28170, demonstrated that Atr-induced AIF processing
and release is mediated by a cysteine protease.
Besides calpains, two other cysteine proteases are caspases and cathepsins.
Caspases are not localized in the mitochondria (van Loo et al., 2002a). Cysteine
cathepsins B, L, and S activity is observed in the mitochondria, and they may be
involved in AIF processing (Yuste et al., 2005; Chaitanya and Babu, 2008). Cathepsin
inhibitor CA-074 inhibited Atr-induced AIF release, though not completely, indicating a
positive role of cathepsins to a certain extent in Atr-induced AIF processing and release.
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Cathepsin B is a lysosomal protease but its alternatively spliced variant lacking exon 2
and 3 is targeted to mitochondria (Muntener et al., 2004) and it is catalytically inactive
(Baici et al., 2006). Moreover, cathepsin B knockout did not prevent AIF release induced
by DNA damage (Moubarak et al., 2007).
Lack of AIF processing in the SH-SY5Y mitochondria despite endogenous
mitochondrial µ-calpain activation suggests that endogenous mitochondrial µ-calpain
activation is not sufficient for AIF processing. Possible explanations could be that the
cleavage site of AIF is sterically hindered in such a way that it is not accessible to the
endogenous mitochondrial µ-calpain or AIF and endogenous mitochondrial µ-calpain are
located in separate mitochondrial intermembrane space compartments. We also
observed that following mitochondrial solubilization AIF processing and endogenous
mitochondrial µ-calpain activation are concomitant and both of the above mentioned
events are susceptible to MDL28170. After mitochondrial solubilization steric hindrance
and compartmentalization are lost, AIF may become accessible to the endogenous
mitochondrial µ-calpain. MDL28170 susceptibility of AIF truncation in the Ca+2 paradigm,
like Atr model, demonstrates that AIF processing is mediated by a cysteine protease.
Calpains are the only known mitochondrial calcium dependent cysteine proteases.
However there are several reports regarding the nature of calpains in the mitochondria
besides µ-calpain. Calpain-10, another cysteine protease which is calcium dependent
and sensitive to MDL28170, has also been reported to be present in the mitochondria
(Arrington et al., 2006). A mitochondrial µ-like calpain is also reported to be associated
with mitochondria (Ozaki et al., 2007). The possibility of any other mitochondrial
calpain’s involvement in AIF processing has not been ruled out. Overall it can be
concluded that the activation of endogenous mitochondrial µ-calpain is neither sufficient
nor required for the processing of AIF.
Evidence exists in literature for positive role of µ-calpain in AIF processing but
that may be cytosolic µ-calpain, which has ability to translocate to mitochondria following
cellular death signals (Kuboki et al., 1992; Goll et al., 2003). One paradox which arises
with the above mentioned explanation is the ability of cytosolic µ-calpain to process AIF
and the inability of mitochondrial µ-calpain to process AIF. There is lack of definitive
evidence suggesting a difference between the nature, substrate specificity or structure of
cytosolic or mitochondrial !-calpain although recently Ozaki et al (Ozaki et al., 2007)
demonstrated that mitochondrial calpain was stained with similar antibodies as µ-calpain
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and was inhibited by calpeptin but there were some differences such as lower pH, higher
sensitivity to chymostatin, later elution on chromatography and higher mobility in the
zymogram showing that mitochondrial calpain may be different from µ-calpain, but this
needs further investigation. It is also noteworthy that susceptibility of AIF to protease
processing is also regulated by other factors. The protein scythe interacts with AIF and
regulates its stability (Desmots et al., 2008). AIF susceptibility is also affected by the
redox state of the cell. Normally AIF exists as NAD(P)H bound dimer capable of
interacting with other proteins via a loop. This interaction with proteins protects the AIF
loop from proteolysis and thus AIF helps in organizing cristae and maintaining good
ETC. But a decline in the pool of NAD(P)H or inner membrane remodeling makes AIF a
monomer due to which AIF loop looses attachment with proteins and becomes
susceptible to the proteases. This cleaved AIF can translocate to nucleus and cause
DNA damage (Churbanova and Sevrioukova, 2008). In nutshell it is fair enough to
conclude that AIF release seems to be regulated by multiple factors (including multiple
proteases/ pathways) such as the type, strength and duration of insult as well as the cell
type and physiological state of the cell. Chapter 3 has shed light on the role of
endogenous mitochondrial µ-calpain in AIF processing.
It is widely appreciated that there is difference in the nature of mitochondria from
various organs in terms of their susceptibility to various insults, their respiratory
capacities, their ion homeostasis capabilities and also their mechanism of mPTP
induction (Hulbert et al., 2006; Shalbuyeva et al., 2006; Dubinsky, 2009). These
differences may account for differences of tissue specific response to similar insults.
Understanding the nature of these differences can account for some of the specific
organ properties. We observed marked differences in the liver and brain mitochondria in
tAIF release following Atr incubation. Following incubation with Atr both liver and brain
mitochondria showed swelling indicating permeability transition pore formation, but only
liver mitochondria showed robust release of tAIF whereas brain mitochondria did not
show any release of tAIF. This suggests a fundamental difference in the mechanism of
tAIF release in the two mitochondrial populations. Brain mitochondria differ from liver
mitochondria in the behavior of the mPTP and its pharmacological regulation (Panov et
al., 2007). Our results indicate that there could be a difference in ANT (adenine
nucleotide translocase), the ligand of Atr, between two mitochondrial populations. ANT
transports ATP/ADP across inner mitochondrial membrane and is an integral inner
mitochondrial membrane protein (Klingenberg, 1980). Three genes of ANT have been
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identified in humans (Cozens et al., 1989; Ku et al., 1990), three isoforms ANT 1, ANT 2
and ANT 3 are found in humans and only ANT 1 and ANT 2 are found in rodents
(Brandolin et al., 1993; Belzacq et al., 2002). Highest ANT 1 mRNA proportions are
found in terminally differentiated tissues like skeletal muscles and brain whereas higher
ANT 2 mRNA is found in proliferative and regenerative tissues like liver, spleen and
fibroblasts (Doerner et al., 1997). This varied level of two isoforms may be the underlying
cause of differential response of two mitochondrial populations to the Atr-induced tAIF
release. It also suggests that Atr may modulate mitochondrial bioenergetics differently in
two mitochondria and hence renders differential release of tAIF. Relatively easier
release of tAIF from liver mitochondria ties well with the fact that liver tissue being
regenerable is more susceptible to cell death whereas brain tissue has a better and
sturdy inbuilt mechanism to prevent the release of IMS cell death inducing proteins. tAIF
release was observed with the outer mitochondrial membrane permeabilizing agent,
alamethicin, in both brain and liver mitochondria. This can be explained by the presence
of unanchored AIF in the mitochondrial IMS.
The studies in isolated mitochondria model system provided novel and insightful
information about the relationship between AIF and endogenous mitochondrial µ-calpain
but it has inherent limitation of not recapitulating in situ scenarios. Mitochondrial µcalpain activation is demonstrated to be not sufficient for AIF processing in isolated
mitochondria (Joshi et al., 2009) but this may not be true in the cell culture system due to
involvement of various cytosolic factors. These factors may facilitate mitochondrial µcalpain’s accessibility to AIF and hence the relationship may be different. µ-Calpain is
also present in the cytosol and has the ability to translocate to the membranes. There is
a possibility of cytosolic µ-calpain processing AIF. It is also known that tAIF is released
from mitochondria and subsequently translocates to the nucleus and induces large scale
DNA fragmentation (50 kB). The role of calpains in AIF nuclear translocation also needs
to be addressed. Chapter 4 of the dissertation was an effort to address the above
mentioned issues. This part of dissertation explored the role of total cellular calpain in
AIF processing and distribution to the nucleus in cell culture model system. NMDA
excitotoxicity induced calpain activation, no AIF processing and showed perinuclear AIF
immunostaining. This demonstrates that calpain activation does not necessarily induce
AIF processing and AIF translocation to the nucleus. We observed that A23187 induced
calpain activation and no AIF processing but still showed AIF nuclear translocation,
which occurred in the presence of MDL28170. This suggests that AIF translocation to
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the nucleus can occur independent of calpain activity and even without processing. This
is in agreement with the recent observation that AIF translocates to the nucleus in
Calpain 4-/- mice, which are functional calpain knockouts, following N-methyl-N'-nitro-Nnitrosoguanidine (MNNG) or NMDA treatment (Wang et al., 2009b). It is also in
agreement with the observation of chapter 3 where Atr treated rat liver isolated
mitochondria released tAIF even in the absence of µ-calpain activation.
There is relatively little information regarding the regulation of mitochondrial µcalpain. An activator of mitochondrial µ-calpain has been identified – Acyl-CoA binding
protein (ACBP) (Melloni et al., 2000; Van Loo et al., 2002b; Shulga and Pastorino,
2006). But no inhibitory component has been yet identified. Initially it was believed that
mitochondrial localization of µ-calpain would segregate the enzyme from its inhibitorcalpastatin, which was thought to be predominantly cytosolic (Taylor et al., 1991;
Kumamoto et al., 1995), and also place µ-calpain in the vicinity of calcium released
following mPTP opening, making its activation easier. Surprisingly, a large amount of
calcium (mM) was required for activating mitochondrial µ-calpain in our experiments
(Joshi et al., 2009). Chapter 5 of the dissertation thus ventured to provide novel insight
into the regulation of mitochondrial µ-calpain. These studies report, for the first time, the
association of calpastatin to the Percoll-enriched mitochondrial fraction of the human
SH-SY5Y cells and rat cerebral cortex. Further we demonstrate by proteinase K
protection assay that calpastatin is inside the mitochondria and by mitochondrial
subfractionation that the calpastatin is localized in the mitochondrial intermembrane
space. This localization is same as that of mitochondrial µ-calpain and may explain why
we need high concentrations (mM) of calcium for activating mitochondrial µ-calpain. One
possible explanation for the lack of involvement of mitochondrial µ-calpain in AIF
processing following mPTP could be the presence of mitochondrial calpastatin.
Calpastatin is nuclear encoded, synthesized in the cytosol and has to be
imported into the mitochondria. The mechanism of calpastatin import into the
mitochondria was addressed by demonstrating that the N-terminal first 30 amino acids of
calpastatin preferentially localize to the mitochondria in the cells transfected with 130XLDCAST-pWPXL. This demonstrates that the N-terminal sequence of the XL domain
of calpastatin is a mitochondrial targeting sequence. There are variety of isoforms of
calpastatin with or without XL domain. Since XL domain has the mitochondrial targeting
sequence, it is possible that XL domain containing calpastatin is exclusively
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mitochondrial. The differential expression of XL domain calpastatin isoform may be a
means to modulate the activity of mitochondrial calpains.
The functional significance for the presence of µ-calpain in the mitochondrial IMS
remains to be determined. Recently NCX, a major means of extruding calcium out of the
mitochondria, was identified as a mitochondrial µ-calpain substrate (Kar et al., 2009).
Calpains are involved in cell adhesion, motility, and dynamics similarly mitochondrial µcalpain may be involved in the mitochondrial dynamics and regulating mitochondrial
morphology. The components of electron transport chain or mPTP may also be
substrates of mitochondrial µ-calpain. The presence of calpastatin has its own
implication and further complicates the scene to understand how mitochondrial calpains
are activated in the mitochondria. Calpastatin binds to EF hands on both the domain IV
and domain VI for inhibiting calpains (Moldoveanu et al., 2008). Mitochondrial calpastatin
will negatively regulate the activity of mitochondrial calpains, but calpain-10, which is
mitochondrial and is reported to be involved in mPTP formation and compromising
complex I activity of ETC by proteolysing subunits NDUFV2 and ND6 (Arrington et al.,
2006), may not be affected by mitochondrial calpastatin as it lacks the domain IV
(Bevers and Neumar, 2008). Further work needs to be done to understand how
mitochondrial calpastatin interacts and regulates mitochondrial !-calpain, the fraction of
total calpastatin in the mitochondria - whether XL domain containing calpastatin is
exclusively mitochondrial, and if there are any changes in the relative expression level of
various calpastatin isoforms, particularly XL domain containing calpastatin during injury,
development or normal physiology.
Finally this dissertation provides novel insights into the mechanism of activation,
function, with regard to AIF processing, and regulation of the endogenous mitochondrial
µ-calpain. We have refuted the hypothesis that localization of µ-calpain in the
mitochondria would make its activation fast, reliable, and easier by proximity to the
activator – calcium and segregation from the inhibitor – calpastatin. We demonstrate that
the activation of endogenous mitochondrial µ-calpain requires relatively high calcium
concentrations. We describe the function of endogenous mitochondrial µ-calpain with
regard to AIF processing. We provide the first evidence that the endogenous
mitochondrial µ-calpain is not involved in the processing of AIF by showing that the
endogenous mitochondrial µ-calpain activation is neither sufficient nor required for the
processing of AIF. We also demonstrate that total cellular calpain activation is not
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sufficient for AIF processing, AIF processing is independent of calpain activation
suggesting involvement of multiple protease pathways, and AIF can translocate to the
nucleus even as full length mature 62 kD unprocessed form. Novel findings of this
dissertation also include the localization of the calpain inhibitor-calpastatin to the
mitochondrial IMS and further unfolding the mechanism of import of calpastatin to the
mitochondria by determining a mitochondrial targeting sequence in the N-terminus of the
XL domain of calpastatin. Although these studies helped to answer several questions
regarding the substrate and regulation of mitochondrial µ-calpain, they raise many more
questions and much remains to be learned.

Copyright © Aashish Joshi 2009
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Appendix
Glossary of Terms
%
!"
#g
#M

- Percentage
- Membrane potential
- Microgram
- Micromolar
°C
- Degree celsius
$
- Alpha
µ
- Mu or Micro
%
- Beta
aa
- Amino acid
AAALC
- American association for
the accreditation of
laboratory animal care
ACBP
- Acyl-CoA binding protein
ADP
- Adenosine diphosphate
AIF
- Apoptosis-inducing factor
Alm
- Alamethicin
ANOVA - Analysis of variance
ANT
- Adenine nucleotide
translocase
Asn
- Asparagine
Arg
- Arginine
ATP
- Adenosine triphosphate
Atr
- Atractyloside
BBB
- Blood brain barrier
BCA
- Bicinchoninic acid
BSA
- Bovine serum albumin
CA
- CA-074
- Calcium
Ca2+
- Calcium chloride
CaCl2
Calpain 4 -/- - Calpain 4 knock out
CAP
- Calpain activating protein
CAST
- Calpastatin
cat. no.
- Catalogue number
CDC
- Center for disease control
CICD
- Caspase-independent cell
death
CNS
- Central nervous system
Cnt
- Control
- Carbon dioxide
CO2
CRMP-3 - Collapsin response
mediator protein
CsA
- Cyclosporine A
CypD
- Cyclophilin D
Cys
- Cysteine
CytC
- Cytochrome C

D
Da
Diablo
DIV
DLAR
DNA
e.g.
E18
E9
EDTA
EGTA
EndoG
ER
ETC
FAD
Fig
g
GFP
H
h
HBSS
HEL
HEPES
HGF
His
Hq
HSP70
IAP
ICC
i.e.
IMM
IMS
IP3R
kB
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- After differential fraction
- Dalton
- Direct IAP binding protein of
low PI
- Days in vitro
- Division of lab animal
resources
- Deoxyribonucleic acid
- Example
- Embryonic day 18 pups
- Embryonic day 9 pups
- Ethylene diamine tetra
acetic acid
- Ethylene glycol tetra acetic
acid
- Endonuclease G
- Endoplasmic reticulum
- Electron transport chain
- Flavin adenine dinucleotide
- Figure
- g-force
- Green fluorescent protein
- Homogenate
- Hour
- Hank’s buffered salts
solution
- Human erythroleukemia
cells
- 4-(2-hydroxyethyl)-1piperazineethanesulfonic
acid
- Hepatocyte growth factor
- Histidine
- Harlequin
- Heat shock protein 70
- Inhibitor of apoptosis
protein
- Immunocytochemistry
- That is
- Inner mitochondrial
membrane
- Intermembrane space
- Inositol triphosphate
receptor
- Kilobase

KCl
kD
KH2PO4

- Potassium chloride
- Kilodalton
- Potassium dihydrogen
phosphate
KOH
- Potassium hydroxide
Lys
- Lysine
M
- Mitochondrial fraction
MCA
- Middle cerebral artery
MDL
- MDL28170
MEM
- Minimum essential media
mg
- Milligram
- Magnesium
Mg2+
MgCl2
- Magnesium chloride
mHSP70 - Mitochondrial HSP70
MIB
- Mitochondrial isolation
buffer
min
- Minutes
ml
- Milliliter
MLS
- Mitochondrial localization
signal
MTS
- Mitochondrial targeting
sequence
mM
- Millimolar
MNNG
- N-Methyl-N’-Nitro-NNitrosoguanidine
MP
- Mitoplast fraction
mPTP
- Mitochondrial permeability
transition pore
mtDNA
- Mitochondrial DNA
mRNA
- Messenger RNA
RNA
- Ribonucleic acid
NA
- Not applicable
NAD(P)H - Nicotinamide adenine
dinucleotide phosphate
NADH
- Nicotinamide adenine
dinucleotide
NCX
- Sodium calcium exchanger
NFKB
- Nuclear factor kappa b
N
- Amino terminus
NLS
- Nuclear localization signal
MPP+
- 1-methyl-4phenylpyridinium
nM
- Nanomolar
NMDA
- N-methyl-D-aspartic acid
NO
- Nitric oxide
NS
- Non significant
OMM
- Outer mitochondrial
membrane
p53
- Protein 53
PAGE
- Polyacrylamide gel
electrophoresis

PAR
PARG
PARP
PBR
PBS
PCR
PD
PK
PKA
PKC
PMSF
ROS
rpm
s
SDS
SEM
SERCA
siRNA
Smac
tAIF
TBI
tBid
TBS
TIM 22
TIM 23
TNF
TOM
TOB
tSCI
TTBS
Tx
uM
VDAC
Zn2+
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- Poly-ADP ribose
- Poly-ADP ribose
polymerase glycohydrolase
- Poly-ADP ribose
polymerase
- Peripheral benzodiazepine
receptor
- Phosphate buffered saline
- Polymerase chain reaction
- PD150606
- Proteinase K
- Protein kinase A
- Protein kinase C
- Phenyl methane sulfonyl
fluoride
- Reactive oxygen species
- Revolutions per minute
- Seconds
- Sodium dodecyl sulfate
- Standard error of mean
- Sarcoplasmic endoplasmic
reticulum calcium ATPase
- Small interfering RNA
- Second mitochondrial
activator of caspases
- Truncated AIF
- Traumatic brain injury
- Truncated Bid
- Tris buffered saline
- Translocase of inner
membrane 22
- Translocase of inner
membrane 23
- Tumor necrosis factor
- Translocase of outer
membrane
- Topogenesis of
mitochondrial outermembrane !-barrel proteins
- Traumatic spinal cord injury
- Tween-Tris buffered saline
- Triton X
- Micromolar
- Voltage dependent anion
channel
- Zinc
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3. Calpastatin localization in the mitochondrial intermembrane space.
Aashish Joshi, Vimala Bondada, and James W. Geddes (In Preparation)
4. Role of calpain in the processing and distribution of apoptosis-inducing factor.
Aashish Joshi, Vimala Bondada, and James W. Geddes (In Preparation)
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PUBLISHED ABSTRACTS
1. Intraspinal MDL28170 microinjection improves functional and pathological outcome
following spinal cord injury.
Yu CG, Joshi A, Geddes JW
Journal of Neurotrauma, Volume: 25, Issue: 7, Pages: 833-840, Published: Jul 2008
2. Targeting ERK2 with lentiviral shRNA improves tissue sparing and locomotor
function after spinal cord injury.
Yu CG, Yezierski RP, Joshi A, Kashif Raza, Yanzhang Li, and James W. Geddes
Journal of Neurotrauma, Volume: 25, Issue: 7, Pages: 910-910, Meeting Abstract:
P227 Published: Jul 2008

3. The calcium dependent cysteine protease !-calpain is located in the mitochondrial
intermembrane space.
Matthew Garcia, Rama Krishna Badugu, Vimala Bondada, Aashish Joshi, and
James W Geddes
The FASEB Journal, 2008;22:1017.3.
POSTER PRESENTATIONS
1. Calpastatin localization in the mitochondrial intermembrane space.
Aashish Joshi, Vimala Bondada, and James W. Geddes.
Kentucky Spinal Cord and Head Injury Research Trust symposium, Louisville, KY –
2009.
2. Mitochondrial !-calpain is not involved in the processing of apoptosis-inducing factor.
Aashish Joshi, Vimala Bondada, and James W. Geddes.
Neuroscience Day, Blue Grass Chapter - Society for Neuroscience, Lexington, KY –
2009.
3. Targeting ERK2 with lentiviral shRNA improves tissue sparing and locomoter
function following spinal cord injury in rats.
Cheng-guang Yu, R.P. Yezierski, Aashish Joshi, Kashif Raza, Yanzhang Li, and
James W. Geddes.
National Neurotrauma Society meeting, Orlando, FL – 2008.
4. Intraspinal MDL28170 microinjection improves functional and pathological outcome
following spinal cord injury.
Cheng-guang Yu, Aashish Joshi, and James W. Geddes.
National Neurotrauma Society meeting, Orlando, FL – 2008.
5. Increased calpain 1 expression during CNS development corresponds with a shift to
caspase-independent neuron death.
Yanzhang Li, Vimala Bondada, Aashish Joshi, and James W. Geddes.
Biology of Calpains in Health and Disease, Snowmass Village, CO – 2007.
6. Is mitochondrial µ-calpain involved in AIF release and caspase-independent cell
death?
Aashish Joshi, Vimala Bondada, Mathew Garcia, and James W. Geddes.
Society for Neuroscience 37th annual meeting, San Diego, CA – 2007
7. Inhibition of ERK1/2 by U0126 for spinal cord injury.
Cheng-guang Yu, Aashish Joshi, and James W. Geddes.
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Society for Neuroscience 37th annual meeting, San Diego, CA – 2007.
8. Mitochondrial µ-calpain: Role in caspase-independent cell death.
Aashish Joshi, Yanzhang Li, Ramakrishna Badugu, Vimala Bondada, Mathew
Garcia, Mark Prendergast, and James W. Geddes.
Kentucky Spinal Cord and Head Injury Research Trust Symposium (KSCHIRT),
Louisville, KY – 2007.
9. Calpain-1 is located in the mitochondrial intermembrane space.
Mathew Garcia, Vimala Bondada, Aashish Joshi, James W. Geddes.
Society for Neuroscience 36th annual meeting, Atlanta, GA – 2006.
10. !-calpain is located in the mitochondria.
Mathew Garcia, Vimala Bondada, Aashish Joshi, J.W. Geddes.
Society for Neuroscience 35th annual meeting, Washington DC – 2005.
HONORS AND AWARDS
2009

Kentucky opportunity fellowship (fall semester), University of
Kentucky, KY, USA.

2009

Myrle E. and Verle D. Nietzel visiting distinguished faculty
program award, University of Kentucky, Lexington, KY, USA.

2008

Selected for attending mitochondrial mini symposium: emergence
and convergence, organized by nature genetics and nature
neurosciences at Duke University, Durham NC, USA.

2008

Kentucky opportunity fellowship, University of Kentucky, KY,
USA.

2007

Graduate school travel award for the society for neuroscience
37th annual meeting, San Diego, CA - University of Kentucky,
Lexington, KY, USA.

2005

Letter of appreciation, from Director of Integrated Biomedical
Sciences (IBS) Ph.D. program, University of Kentucky, for
excellent academic performance.

2003

Fourth merit position in the faculty of veterinary medicine and
animal science, Rajasthan Agriculture University, India.

2000 - 2001

Best cadet of National Service Scheme (NSS), India.

1997

National talent scholarship in agriculture sciences by Indian
Council of Agricultural Research (ICAR), New Delhi, India.

1991 - 2003

State Bank of Bikaner and Jaipur (SBBJ) scholarship for excellent
academic performance, India.

PROFESSIONAL AFFILIATIONS
2005 - Present

Society for Neuroscience
Bluegrass Chapter of the Society for Neuroscience

2003 - Present

Indian Veterinary Council
Rajasthan State Veterinary Council
139

TEACHING EXPERIENCE
2008 Fall

Teaching Assistant (TA) - ANA 109 (002): Anatomy & Physiology
for nursing I

2007 Spring

Teaching Assistant (TA) - MD 817/ANA 636: Advanced
Neuroanatomy/Medical Neuroanatmony

SERVICE AND LEADERSHIP ACTIVITIES
•

Co-organizer of the Department of Anatomy and Neurobiology, University of
Kentucky College of Medicine “Translational Neuroscience: Models of Aging 2008
Lexington Conference”- October 2008.

•

Served as a Judge thrice in Kentucky State Science & Engineering Fair (KSSEF)
held at Eastern Kentucky University, Richmond, KY - March 2009, March 2008 and
March 2007.

•

Co-organizer of the Department of Anatomy and Neurobiology, University of
Kentucky College of Medicine “Lexington Conference on RNA therapy for
Neurodegenerative Diseases”- April 2006.
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